Document:

<PAGE>
                                                                    Exhibit 10.3

          Confidential Materials omitted and filed separately with the

         Securities and Exchange Commission. Asterisks denote omissions.

                        MANUFACTURING SERVICES AGREEMENT

                                     BETWEEN

                          PATHEON PHARMACEUTICALS INC.

                                       AND

                           CRITICAL THERAPEUTICS, INC.

                                  JUNE 28, 2005

<PAGE>

                                TABLE OF CONTENTS
<TABLE>
<S>                                                                           <C>
ARTICLE 1..................................................................    1

INTERPRETATION.............................................................    1
   1.1     DEFINITIONS. ...................................................    1
   1.2     CURRENCY........................................................    4
   1.3     SECTIONS AND HEADINGS...........................................    4
   1.4     SINGULAR TERMS..................................................    5
   1.5     SCHEDULES.......................................................    5

ARTICLE 2..................................................................    5

PATHEON'S MANUFACTURING SERVICES...........................................    5
   2.1     MANUFACTURING SERVICES..........................................    5
   2.2     STANDARD OF PERFORMANCE.........................................    6

ARTICLE 3..................................................................    8

CLIENT'S OBLIGATIONS.......................................................    8
   3.1     PAYMENT. .......................................................    8
   3.2     ACTIVE MATERIAL.................................................    8

ARTICLE 4..................................................................    9

CONVERSION FEES AND COMPONENT COSTS........................................    9
   4.1     FIRST YEAR PRICING. ............................................    9
   4.2     SUBSEQUENT YEARS' PRICING. .....................................    9
   4.3     ADJUSTMENTS TO PRICING. ........................................   10
   4.4     ADJUSTMENTS DUE TO TECHNICAL CHANGES. ..........................   12
   4.5     MULTI-COUNTRY MANUFACTURING AND PACKAGING REQUIREMENTS. ........   12

ARTICLE 5..................................................................   12

ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES.................   12
   5.1     ORDERS AND FORECASTS............................................   12
   5.2     RELIANCE BY PATHEON. ...........................................   13
   5.3     MINIMUM ORDERS. ................................................   15
   5.4     SHIPMENTS. .....................................................   15
   5.5     LATE SHIPMENT AND SHELF LIFE....................................   15
   5.6     INVOICES AND PAYMENT............................................   16

ARTICLE 6..................................................................   17
</TABLE>

                                      -i-

<PAGE>

<TABLE>
<S>                                                                           <C>
PRODUCT CLAIMS AND RECALLS.................................................   17
   6.1     PRODUCT CLAIMS. ................................................   17
   6.2     PRODUCT RECALLS AND RETURNS.....................................   18
   6.3     DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS...................   19
   6.4     CUSTOMER QUESTIONS AND COMPLAINTS. .............................   19
   6.5     SOLE REMEDY.....................................................   20

ARTICLE 7..................................................................   20

CO-OPERATION...............................................................   20
   7.1     QUARTERLY REVIEW................................................   20
   7.2     GOVERNMENTAL AGENCIES. .........................................   20
   7.3     RECORDS AND ACCOUNTING BY PATHEON. .............................   20
   7.4     INSPECTION. ....................................................   21
   7.5     ACCESS. ........................................................   21
   7.6     REPORTS.........................................................   21
   7.7     FDA FILINGS.....................................................   21
   7.8     TECHNOLOGY TRANSFERS............................................   23

ARTICLE 8..................................................................   23

TERM AND TERMINATION.......................................................   23
   8.1     INITIAL TERM....................................................   23
   8.2     TERMINATION BY PATHEON OR CLIENT. ..............................   23
   8.3     TERMINATION FOR CAUSE...........................................   23
   8.4     PRODUCT DISCONTINUATION. .......................................   24
   8.5     OBLIGATIONS ON TERMINATION. ....................................   24

ARTICLE 9..................................................................   25

REPRESENTATIONS, WARRANTIES AND COVENANTS..................................   25
   9.1     AUTHORITY. .....................................................   25
   9.2     NON-INFRINGEMENT................................................   25
   9.3     DEBARRED PERSONS................................................   26
   9.4     PERMITS.........................................................   26
   9.5     COMPLIANCE WITH LAWS............................................   26
   9.6     NO WARRANTY.....................................................   26

ARTICLE 10.................................................................   26

REMEDIES AND INDEMNITIES...................................................   26
   10.1    CONSEQUENTIAL DAMAGES...........................................   26
   10.2    LIMITATION OF LIABILITY.........................................   27
</TABLE>

                                      -ii-

<PAGE>

<TABLE>
<S>                                                                           <C>
   10.3    PATHEON. .......................................................   27
   10.4    CLIENT..........................................................   27

ARTICLE 11.................................................................   28

CONFIDENTIALITY............................................................   28

ARTICLE 12.................................................................   29

DISPUTE RESOLUTION.........................................................   29
   12.1    COMMERCIAL DISPUTES. ...........................................   29
   12.2    TECHNICAL DISPUTE RESOLUTION. ..................................   29

ARTICLE 13.................................................................   30

MISCELLANEOUS..............................................................   30
   13.1    INVENTIONS......................................................   30
   13.2    INTELLECTUAL PROPERTY...........................................   31
   13.3    INSURANCE. .....................................................   31
   13.4    INDEPENDENT CONTRACTORS.........................................   31
   13.5    NO WAIVER.......................................................   31
   13.6    ASSIGNMENT......................................................   31
   13.7    FORCE MAJEURE...................................................   32
   13.8    ADDITIONAL PRODUCT. ............................................   32
   13.9    NOTICES.........................................................   32
   13.10   SEVERABILITY....................................................   33
   13.11   ENTIRE AGREEMENT................................................   34
   13.12   OTHER TERMS.....................................................   34
   13.13   NO THIRD PARTY BENEFIT OR RIGHT. ...............................   34
   13.14   EXECUTION IN COUNTERPARTS. .....................................   34
   13.15   GOVERNING LAW. .................................................   35
</TABLE>

                                      -iii-

<PAGE>

                        MANUFACTURING SERVICES AGREEMENT

          THIS MANUFACTURING SERVICES AGREEMENT (THE "AGREEMENT") made as of the
22 day of June, 2005

BETWEEN:

          PATHEON PHARMACEUTICALS INC.,
          a corporation existing under the laws of the State of Delaware,

          (hereinafter referred to as "PATHEON"),

                                     - and -

          CRITICAL THERAPEUTICS, INC.,
          a corporation existing under the laws of the State of Delaware,

          (hereinafter referred to as the "CLIENT").

          THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred
and the obligations assumed herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each
party), and intending to be legally bound the parties agree as follows:

                                    ARTICLE 1

                                 INTERPRETATION

1.1  DEFINITIONS.

          The following terms shall, unless the context otherwise requires, have
the respective meanings set out below and grammatical variations of such terms
shall have corresponding meanings:

     "ACTIVE MATERIAL" means the compound
     1-(1-benzo[b]thien-2-ylethyl)-1-hydroxyurea, also known as zileuton;

     "ACTIVE MATERIAL REIMBURSEMENT VALUE" means the value to be attributed to
     the Active Material for the purposes of Section 2.3 of this Agreement, as
     set forth in Schedule D hereto;

<PAGE>

     "AFFILIATE" means:

     (a)  a business entity which owns, directly or indirectly, a majority
          interest in a party to this Agreement, by stock ownership or
          otherwise; or

     (b)  a business entity at least 50% of which is owned by a party to this
          Agreement, either directly or indirectly, by stock ownership or
          otherwise; or

     (c)  a business entity, the majority ownership of which is directly or
          indirectly common to the majority ownership of a party to this
          Agreement;

     "ANNUAL VOLUME" means the minimum volume of Product to be manufactured by
     Patheon in any Year of this Agreement for purposes of calculating the fees
     as set forth in Schedule B hereto;

     "BATCH DOCUMENTATION" means all documentation relating to the production
     and analysis of the Product including, but not limited to, executed
     manufacturing and packaging batch records, in process and product release
     test data, certificate of compliance with cGMPs and certificates of
     analysis for all Products, Components and Active Material, as set forth in
     Article 3 of the Quality Agreement.

     "BUSINESS DAY" means a day other than a Saturday, Sunday or a day that is a
     statutory holiday in the State of Ohio and/or the Commonwealth of
     Massachusetts;

     "CGMPS" means current good manufacturing practices as described in Parts
     210 and 211 of Title 21 of the United States' Code of Federal Regulations
     together with the latest FDA guidance documents pertaining to manufacturing
     and quality control practice, all as updated, amended and revised from time
     to time;

     "COMMENCEMENT DATE" means the first day upon which commercial manufacturing
     shall commence;

     "COMPONENTS" means, collectively, all packaging components, raw materials
     and ingredients (including labels, product inserts and other labelling for
     the Products), required to be used in order to produce the Products in
     accordance with the Specifications, other than the Active Material;

     "CONFIDENTIALITY AGREEMENT" means the agreement relating to the
     non-disclosure of confidential information between Patheon and the Client
     dated May 20, 2004 and attached hereto as Schedule J;

     "DEFICIENCY NOTICE" shall have the meaning ascribed thereto in Section
     6.1(a);

     "EXW" means ex works, as that term is defined in INCOTERMS 2000;

                                      -2-

<PAGE>

     "FDA" means the United States government department known as the Food and
     Drug Administration;

     "FIRM ORDERS" has the meaning specified in Section 5.1(b);

     "INTELLECTUAL PROPERTY" includes, without limitation, rights in patents,
     patent applications, formulae, trade-marks, trade-mark applications,
     trade-names, Inventions, copyrights, and industrial designs;

     "INVENTION" means information relating to any innovation, improvement,
     development, discovery, computer program, device, trade secret, method,
     know-how, process, technique or the like, whether or not written or
     otherwise fixed in any form or medium, regardless of the media on which it
     is contained and whether or not patentable or copyrightable;

     "INVENTORY" means all inventories of Components and work-in-process
     produced or held by Patheon in connection with the manufacture of the
     Products but, for greater certainty, does not include the Active Material;

     "MANUFACTURING SERVICES" means the manufacturing, quality control, quality
     assurance and stability testing, packaging and related services, as
     contemplated in this Agreement, required to produce Products from Active
     Material and Components;

     "MANUFACTURING SITE" means Patheon's facilities located at 2110 East
     Galbraith Road, Cincinnati, Ohio;

     "MINIMUM RUN QUANTITY" means the minimum number of batches of a Product to
     be produced during the same cycle of manufacturing as set forth in Schedule
     B hereto;

     "PRODUCT" means an immediate release tablet formulation of the Active
     Material as described in the sNDA submitted by Client to the FDA;

     "QUALITY AGREEMENT" means the agreement dated April 7, 2005 entered into
     between the parties hereto setting out the quality assurance standards to
     be applicable to the Manufacturing Services provided by Patheon, which
     agreement is attached hereto as Schedule G;

     "SPECIFICATIONS" means the file, for each Product, which is provided by the
     Client to Patheon in accordance with the procedures listed in Schedule A
     hereto and which contains documents relating to such Product, including,
     without limitation:

     (a)  specifications for Active Material and Components including the test
          methods for the Active Material and Components;

                                      -3-

<PAGE>

     (b)  manufacturing specifications, directions and processes;

     (c)  storage requirements;

     (d)  all environmental, health and safety information relating to the
          Product including material safety data sheets; and

     (e)  the finished Product specifications, packaging specifications and
          shipping requirements for each Product including test methods for
          Products;

     all as updated, amended and revised from time to time by the Client in
     accordance with the terms of this Agreement;

     "TECHNICAL DISPUTE" has the meaning specified in Section 12.2;

     "TERRITORY" means in the geographic area of the United States, its
     territories and possessions;

     "THIRD PARTY RIGHTS" means the Intellectual Property of any third party;

     "USP" shall mean the then current United States Pharmacopeia;

     "WAREHOUSE SITE" means Patheon Pharmaceuticals Inc., Blue Ash Warehouse,
     4750 Lake Forest Drive, Cincinnati, OH 45242, USA

     "YEAR" means in the case of the first year of this Agreement the period
     from the Commencement Date up to and including December 31 of the same
     calendar year, and thereafter shall mean a calendar year.

1.2  CURRENCY.

          Unless otherwise indicated, all monetary amounts are expressed in this
Agreement in the lawful currency of the United States of America.

1.3  SECTIONS AND HEADINGS.

          The division of this Agreement into Articles, sections, subsections
and Schedules and the insertion of headings are for convenience of reference
only and shall not affect the interpretation of this Agreement. Unless otherwise
indicated, any reference in this Agreement to a Section or Schedule refers to
the specified Section or Schedule to this Agreement. In this Agreement, the
terms "THIS AGREEMENT", "HEREOF", "HEREIN", "HEREUNDER" and similar expressions
refer to this Agreement and not to any particular part, Section, Schedule or the
provision hereof.

                                      -4-

<PAGE>

1.4  SINGULAR TERMS.

          Except as otherwise expressly provided herein or unless the context
otherwise requires, all references to the singular shall include the plural and
vice versa.

1.5  SCHEDULES.

          The following Schedules are attached to, incorporated in and form part
of this Agreement:

          Schedule A - Procedure for Shipment and Acceptance of Product
                       Specifications and Test Methods
          Schedule B - Minimum Run Quantity, Minimum Annual Volume & Fees
          Schedule C - Stability Testing
          Schedule D - Active Material & Active Material Reimbursement Value
          Schedule E - Batch Numbering & Expiration Dates
          Schedule F - Technical Dispute Resolution
          Schedule G - Quality Agreement
          Schedule H - Quarterly Active Material Inventory Report
          Schedule I - Report of Annual Active Material Inventory
                       Reconciliation and Calculation of Actual Annual Yield
          Schedule J - Confidentiality Agreement

                                    ARTICLE 2

                        PATHEON'S MANUFACTURING SERVICES

2.1  MANUFACTURING SERVICES.

          Patheon shall provide the Manufacturing Services for the Territory for
the fees specified in Schedules B and C in order to produce Products for the
Client solely at the Manufacturing Site. Active Material, Products and
Components shall only be stored at the Warehouse Site. If Manufacturing Services
have not commenced within 12 months of the Effective Date, Patheon reserves the
right to amend fees set out in Schedules B and C. Client shall purchase at least
50% of its requirements of Products for sale in the Territory for each Year of
the Term from Patheon pursuant to the terms of this Agreement. In providing the
Manufacturing Services, Patheon shall perform each of the following services:

     (a)  Conversion of Active Material and Components. Patheon shall convert
          Active Material and Components into Products.

     (b)  Quality Control and Quality Assurance. Patheon shall perform the
          quality control and quality assurance testing specified in the Quality
          Agreement. Each time

                                      -5-

<PAGE>

          Patheon ships Products to the Client or the Client's designated agent,
          Patheon shall provide the Client with a certificate of analysis that
          sets out the test results for each batch of Products, and that
          certifies that such batch has been evaluated by Patheon's Quality
          Control/Quality Assurance department and that the Products comply with
          the Specifications. At the same time, Patheon shall provide the Client
          with a certificate of cGMPs conformance for the Product. If requested
          by the Client, Patheon shall also provide full manufacturing and
          packaging batch records and release raw data to Client.

     (c)  Active Material and Components. Patheon shall purchase all Components
          with the exception of those that are supplied by the Client. Further,
          Patheon shall test all Components and Active Material to USP standards
          or as otherwise specified by the Specifications, at Patheon's expense.

     (d)  Stability Testing. Patheon shall conduct stability testing on the
          Products in accordance with the protocols set out in the
          Specifications for the separate fees specified in Schedule C. Patheon
          shall not make any changes to these testing protocols without prior
          written approval from the Client. In the event that any batch of
          Products fails stability testing, Patheon and the Client shall jointly
          determine the proceedings and methods to be undertaken to investigate
          the causes of such failure, including which party shall bear the cost
          of such investigation, provided that Patheon shall not be liable for
          any such costs unless there has been a failure by it to provide the
          Manufacturing Services in accordance with the Specifications and
          cGMPs. Patheon will provide any and all data and results relating to
          the stability testing upon request by the Client.

     (e)  Packaging. Patheon shall package the Products with labels, product
          inserts and other packaging as set out in the Specifications. In
          addition, Patheon shall make arrangements for and implement the
          imprinting of batch numbers and expiration dates for each Product
          shipped. Such batch numbers and expiration dates shall be affixed on
          the Products and on the shipping carton of each Product as outlined in
          the Specifications and as required by cGMPs. The system used by
          Patheon for batch numbering and expiration dates is detailed in
          Schedule E hereto. The Client may, in its sole discretion, make
          changes to labels, product inserts and other packaging for the
          Products, which changes shall be submitted by the Client to all
          applicable governmental agencies and other third parties responsible
          for the approval of the Products. Patheon hereby consents to the use
          of its name on the Products label or anywhere else on the Products.

2.2  STANDARD OF PERFORMANCE.

          Patheon shall provide the Manufacturing Services in accordance with
the Specifications and cGMPs.

                                      -6-

<PAGE>

2.3  ACTIVE MATERIAL YIELD.

     (a) Reporting. Patheon shall provide the Client with a quarterly inventory
report of the Active Material held by Patheon in accordance with the inventory
report form annexed hereto as Schedule H, which shall contain the following
information for such quarter:

     QUANTITY RECEIVED: The total quantity of Active Material that complies with
     the Specifications and is received at a Manufacturing Site during the
     applicable period.

     QUANTITY DISPENSED: The total quantity of Active Material dispensed at a
     Manufacturing Site during the applicable period. The Quantity Dispensed is
     calculated by adding the Quantity Received to the inventory of Active
     Material that complies with the Specifications and is held at the beginning
     of the applicable period, less the inventory of Active Material that
     complies with the Specifications and is held at the end of such period. The
     Quantity Dispensed shall only include Active Material received and
     dispensed in connection with commercial manufacturing of Products and, for
     certainty, shall not include any Active Material received or dispensed in
     connection with technical transfer activities or development activities
     during the applicable period, including, without limitation, any
     regulatory, stability, validation or test batches manufactured during the
     applicable period.

     QUANTITY CONVERTED: The total amount of Active Material contained in the
     Products produced with the Quantity Dispensed (including any additional
     Products produced in accordance with Section 6.1 or 6.2), delivered by
     Patheon and, except as provided in Section 5.5(c), not rejected, recalled
     or returned in accordance with Section 6.1 or 6.2 as a result of a failure
     by Patheon to provide Manufacturing Services in accordance with
     Specifications and cGMPs.

Within 60 days after the end of each Year, Patheon shall prepare an annual
reconciliation of Active Material in accordance with the reconciliation report
form annexed hereto as Schedule I including the calculation of the "ACTUAL
ANNUAL YIELD" or "AAY" for the Product at the Manufacturing Site during the
Year, which AAY is the percentage of the Quantity Dispensed that was converted
to Products and is calculated as follows:

                       Quantity Converted during the Year
                       ----------------------------------
                       Quantity Dispensed during the Year

After Patheon has produced a minimum of [**] commercial and validation
production batches of Product and has produced commercial and validation
production batches for at least [**] months at a Manufacturing Site
(collectively, the "TARGET YIELD DETERMINATION BATCHES") pursuant to this
Agreement, the Parties will mutually agree on the target yield in respect of
such Product at such Manufacturing Site (each, a "TARGET YIELD"); provided,
however, that the Target Yield Determination Batches shall not include any
batches that, in Patheon's reasonable judgment,

                                      -7-

<PAGE>

were produced in production runs involving technical difficulties or involving
an extraordinary loss of Active Material. Thereafter, Patheon shall strive to
maintain Actual Annual Yield levels for each Product above the applicable Target
Yield.

     (b) Shortfall Calculation. If the Actual Annual Yield falls more than [**]
percent below the respective Target Yield in a Year, then the shortfall for such
Year (the "Shortfall") shall be determined based on the following calculation:

     [**]

The Shortfall shall be disclosed by Patheon to the Client on the reconciliation
report prepared in the form annexed hereto as Schedule I.

     (c) Reimbursement. Patheon shall reimburse the Client for any Shortfall in
a Year. Each payment under this Section 2.3 shall be summarized on the
reconciliation report prepared in the form attached hereto as Schedule I and
shall be made 30 days following the end of each Year.

     (d) Maximum Reimbursement. Notwithstanding the foregoing provisions of this
Section 2.3, Patheon's liability for Active Material calculated in accordance
with this Section 2.3 for any Product in a Year shall not exceed, in the
aggregate, the Maximum Reimbursement Value set forth in Schedule D hereto.

     (e) No Material Breach. It shall not constitute a material breach of this
Agreement by Patheon, for the purposes of Section 8.2(a), if the Actual Annual
Yield is less that the Target Yield.

                                    ARTICLE 3

                              CLIENT'S OBLIGATIONS

3.1  PAYMENT.

          Pursuant to the terms of this Agreement, the Client shall pay Patheon
for the provision of the Manufacturing Services according to the fees specified
in Schedules B and C hereto (such fees being subject to adjustment in accordance
with the terms hereof).

3.2  ACTIVE MATERIAL.

          The Client shall, at its sole cost and expense, deliver the Active
Material to Patheon in sufficient quantities and at such times to facilitate the
provision of the Manufacturing

                                      -8-

<PAGE>

Services by Patheon, which Active Material shall be held by Patheon on behalf of
the Client on the terms and subject to the conditions herein contained. The
parties acknowledge and agree that title to the Active Material shall at all
times belong to and remain the property of the Client. Patheon agrees that any
Active Material received by it shall only be used by Patheon to provide the
Manufacturing Services. Patheon's liability with respect to any lost or damaged
Active Material shall be as set forth in Section 10.2(a).

                                    ARTICLE 4

                       CONVERSION FEES AND COMPONENT COSTS

4.1  FIRST YEAR PRICING.

     The fees for the Manufacturing Services (which fees include Component
costs) for the first Year are listed in Schedules B and C and are subject to the
adjustments set forth in Section 4.3.

4.2  SUBSEQUENT YEARS' PRICING.

     The fees for the Manufacturing Services provided pursuant to the terms of
this Agreement during any period following the first anniversary of this
Agreement shall be determined in accordance with the following:

     (a)  Manufacturing and Component Costs. On each yearly anniversary of this
          Agreement, Patheon shall be entitled to adjustment to the fees (i) for
          Manufacturing Services in respect of the Products to reflect
          inflation, which adjustment shall be based on the increase in the
          Consumer Price Index for All Urban Consumers published by US Bureau of
          Labor Statistics in September of the then current Year compared to the
          same month of the preceding Year, unless the parties otherwise agree
          in writing; and (ii) for Component costs to pass on the actual amount
          of any increase or decrease in such costs.

     (b)  Annual Forecast. To the extent that Patheon determines that the
          projections contained in the rolling forecast provided each [**]
          pursuant to Section 5.1(a) necessitate that an adjustment be made to
          the Manufacturing Services fees in respect of any Product, Patheon
          shall be entitled to request an appropriate price adjustment.

     (c)  Pricing Basis. The Client acknowledges that the fee for Manufacturing
          Services in respect of a Product in any Year is quoted based upon the
          Minimum Run Quantity and Annual Volume per Product specified in
          Schedule B or thereafter specified in the forecast provided pursuant
          to clause (b) of this Section 4.2 for the Year and is subject to
          change if the specified Minimum Run Quantity changes or if the Annual
          Volume is not met. For greater certainty, if Patheon and the Client

                                      -9-

<PAGE>

          agree that the Minimum Run Quantity in respect of a Product shall be
          reduced whether as a result of a decrease in Annual Volume or
          otherwise and, as a result of such reduction, Patheon's fees for
          services relating to such Product increase on a per unit basis, then
          Patheon shall be entitled to an increase in the fee for Manufacturing
          Services in respect of such Product by an amount sufficient to absorb
          such increase.

In connection with a fee adjustment pursuant to clause (a) of this Section 4.2,
Patheon shall deliver to the Client by not later than November 1st of each Year
a revised Schedule B in draft form and a statement outlining the percentage
increase in the US Consumer Price Index for All Urban Consumers upon which such
fee adjustment is based. In connection with all fee adjustment requests pursuant
to clauses (b) and (c) of this Section 4.2, Patheon shall deliver to the Client
by not later than November 1st of each Year a revised Schedule B in draft form
and such budgetary pricing information or other documentation reasonably
sufficient to demonstrate that a fee adjustment is justified, provided that
Patheon shall have no obligation to provide any supporting documents to the
extent such documents are subject to obligations of confidentiality by Patheon
to its suppliers. Upon delivery of such a request, each of the Client and
Patheon shall forthwith use all reasonable efforts to agree on a revised fee for
the Manufacturing Services in respect of each affected Product and Schedule B
shall be amended accordingly. Such revised fee shall be effective with respect
to any Product delivered after the end of the then current Year.

4.3  ADJUSTMENTS TO PRICING.

     During any Year of this Agreement, the fees set out in Schedule B shall be
subject to adjustment in accordance with the following:

     (a)  Volume Reduction. If at any time and from time to time Patheon
          determines, acting reasonably and based on the forecasts and Firm
          Orders received from the Client, that the current Minimum Run
          Quantities (including, without limitation, any permanent reductions in
          volumes) relating to a specific Product will constitute no more than
          [**]% of the Annual Volume for that Product specified in Schedule B
          hereto or, if applicable, any revised Annual Volume hereinafter agreed
          to by the parties, then Patheon shall be entitled to request an
          adjustment to the fee for Manufacturing Services in respect of that
          Product to reflect the increased costs that Patheon will incur as a
          result of the reduced volumes. If at any time and from time to time
          the Client determines, acting reasonably and based upon the forecasts
          and Firm Orders submitted to Patheon, that the current Minimum Run
          Quantities (including, without limitation, any permanent reduction in
          volumes) relating to a specific Product will constitute greater than
          [**]% of the Annual Volume for that Product specified in Schedule B
          hereto, or if applicable, any revised Annual Volume hereinafter agreed
          to by the parties, then the Client shall be entitled to request an
          adjustment to the fee for Manufacturing Services in respect of that
          Product to reflect the decreased costs that Patheon will incur as a

                                      -10-

<PAGE>

          result of the increased volumes. To the extent that the fee for
          Manufacturing Services in respect of a Product has been previously
          adjusted pursuant to this clause (a) to reflect reduced or increased
          volumes, the adjustment provided in this clause (a) shall operate
          based on the fees attributed to such Product at the time the last of
          such adjustments were made.

     (b)  Extraordinary Increases in Component Costs. If at any time market
          conditions result in Patheon's cost of Components being materially
          greater than normal forecasted increases, then Patheon shall be
          entitled to request an adjustment to the fee for Manufacturing
          Services in respect of any affected Product to compensate it for such
          increased Component costs. For the purposes of this clause (b),
          changes materially greater than normal forecasted increases shall be
          considered to have occurred if: (i) the cost of a Component increases
          by [**]% of the cost for that Component upon which the most recent fee
          quote was based; or (ii) the aggregate cost for all Components
          required to manufacture a Product increases by [**]% of the total
          Component costs for such Product upon which the most recent fee quote
          was based. To the extent that Component costs have been previously
          adjusted pursuant to clause (a) of Section 4.2 or this clause (b) to
          reflect an increase in the cost of one or more Components, the
          adjustments provided for in (i) and (ii) above shall operate based on
          the then current price of the last adjustment to Component costs.

     (c)  Cost Reduction. Patheon agrees that it will attempt to increase the
          efficiency of the production process in order to reduce the cost of
          the Product. In the event that Patheon decreases the cost of
          manufacturing the Product, including, but not limited to, by reducing
          the cost basis of the Components utilized for the production of
          Product, whether such cost basis reduction is through the placement of
          bulk orders, change of vendors or otherwise in accordance with the
          terms of this Agreement, then [**]% of the net reduction of cost shall
          be credited to Client through a reduction of the fees per unit for the
          Product.

In connection with a fee adjustment request pursuant to this Section 4.3,
Patheon shall deliver to the Client a revised Schedule B and such budgetary
pricing information, adjusted Component costs or other documentation reasonably
sufficient to demonstrate that a fee adjustment is justified, provided that
Patheon shall have no obligation to provide any supporting documents to the
extent such documents are subject to obligations of confidentiality by Patheon
to its suppliers. Upon delivery of such a request, each of the Client and
Patheon shall forthwith use all reasonable efforts to agree on a revised fee for
the Manufacturing Services in respect of each affected Product and Schedule B
shall be amended accordingly.

                                      -11-

<PAGE>

4.4  ADJUSTMENTS DUE TO TECHNICAL CHANGES.

          Amendments to the Specifications or the Quality Agreement requested by
the Client, other than those mandated by the FDA or other government regulatory
agency (for which Client shall accept reasonable revision of the fees
necessitated by such amendment), will only be implemented following a technical
and cost review by Patheon and are subject to the Client and Patheon reaching
agreement as to revisions, if any, to the fees specified in Schedules B or C
necessitated by any such amendment. If the Client accepts a proposed fee change,
the proposed change in the Specifications shall be implemented, and the fee
change shall become effective only with respect to those orders of Products that
are manufactured in accordance with the revised Specifications. In addition, the
Client agrees to purchase, at Patheon's cost therefor (including all costs
incurred by Patheon in connection with the purchase and handling of such
Inventory), all Inventory utilized under the "old" Specifications and purchased
or maintained by Patheon in order to fill Firm Orders or in accordance with
Section 5.2, to the extent that such Inventory can no longer be utilized under
the revised Specifications. Open purchase orders for Components no longer
required under any revised Specifications that were placed by Patheon with
suppliers in order to fill Firm Orders or in accordance with Section 5.2 shall
be cancelled where possible, and where such orders are not subject to
cancellation without penalty, shall be assigned to and satisfied by the Client
and, at Client's option, Client shall take possession of the material in any
such orders. At Client's expense, Patheon shall deliver such Components to a
destination provided by Client.

4.5  MULTI-COUNTRY MANUFACTURING AND PACKAGING REQUIREMENTS.

          If and when the Client decides that it wishes to have Patheon
manufacture the Product for countries in addition to the Territory covered by
this Agreement, then the Client shall inform Patheon of the Component, Active
Material, Product, process and packaging requirements for each new country and
Patheon shall prepare a quotation for consideration by the Client of the
additional costs, if any, and the change over fees for the Product destined for
such new country. The agreed additional Component, Active Material, Product,
process and packaging requirements and related costs and change over fees shall
be set out in a written amendment to this Agreement.

                                    ARTICLE 5

           ORDERS, DELIVERY, INVOICING, PAYMENT, PRODUCT DEFICIENCIES

5.1  ORDERS AND FORECASTS.

     (a) Rolling Forecasts. Concurrent with the execution of this Agreement, the
Client shall provide Patheon with a written [**] forecast of the volume of each
Product that the Client then anticipates will be required to be produced by
Patheon and shipped to the Client or the

                                      -12-

<PAGE>

Client's designee during [**] and each [**] of Firm Orders (as defined below),
[**] of pro forma amounts of Product and [**] of planning horizon. Such forecast
will be updated by the Client [**] or before [**].

     (b) Firm Orders. On or before the [**] in conjunction with the provision of
the rolling forecast outlined in section 5.1(a), the Client shall issue firm
written orders ("FIRM ORDERS") for the Products to be produced and delivered to
the Client on a date not less than [**] from the first day of the calendar month
immediately following the date that the Firm Order is submitted. Such Firm
Orders submitted to Patheon shall specify the Client's purchase order number,
quantities by Product type, batch size, monthly delivery schedule and any other
elements necessary to ensure the timely production and shipment of the Products.
The quantities of Products ordered in such written orders shall be firm and
binding on the Client and shall not be subject to reduction by the Client.
Patheon shall have [**] to object in writing to the Client to any element of a
Firm Order. If Patheon does not object, then such Firm Order shall be binding on
Patheon and no part shall be subject to change by Patheon.

     (c) [**] Forecast. On or before [**], the Client shall provide Patheon with
a written [**] of the volume of each Product the Client then anticipates will be
required to be produced and shipped to the Client during the [**] period.

5.2  RELIANCE BY PATHEON.

          The Client understands and acknowledges that Patheon will rely on the
Firm Orders and rolling forecasts submitted pursuant to Section 5.1(a) and (b)
in ordering the Components required to meet such Firm Orders. In addition, the
Client understands that to ensure an orderly supply of such Components and/or to
achieve economies of scale in the costs, it may be desirable for Patheon to
purchase such Components in sufficient volumes to meet the production
requirements for Products during part or all of the first [**] of the forecasted
periods referred to in Section 5.1(a) or to meet the production requirements of
any longer period agreed to by Patheon and the Client. Accordingly, the Client
authorizes Patheon to purchase Components in order to satisfy the production
requirements for Products for the first [**] contemplated in the most recent
forecast provided by the Client pursuant to Section 5.1(a), and agrees that
Patheon may make such other purchases of Components to meet production
requirements during such longer periods as may be agreed to in writing from time
to time by the Client at the request of Patheon or the Client. Any requests made
by Client for product launch quantities of Product not contemplated in forecasts
or Firm Orders shall only be accepted by Patheon if made in writing by the
Client for the purposes of ordering Components and thereafter shall be treated
as a Firm Order. If Components ordered by Patheon pursuant to Firm Orders or
this Section 5.2 are not included in finished Products purchased by the Client
within [**] after the forecasted month in respect of which such purchases have
been made (or such longer period as the parties may agree) or if such Components
have expired during such period, then the Client shall pay to Patheon its costs
therefor (plus an additional [**]% handling fee); provided, however, that in the
event such unexpired Components are incorporated into Products

                                      -13-

<PAGE>

subsequently purchased by the Client or into third party products manufactured
by Patheon and subsequently purchased by a third party, the Client will receive
credit for any costs of such Components previously paid to Patheon by the
Client.

                                      -14-

<PAGE>

5.3  MINIMUM ORDERS.

          The Client may only order Products in multiples of the Minimum Run
Quantities set out in Schedule B.

5.4  SHIPMENTS.

          Shipments of Products shall be made EXW Patheon's shipping point
unless otherwise mutually agreed. Risk of loss or of damage to Products shall
remain with Patheon until Products are loaded onto the carrier's vehicle by
Patheon for shipment at the EXW point at which time risk of loss or damage shall
transfer to the Client. Patheon shall, in accordance with the Client's
instructions and as agent for the Client, (i) arrange for shipping, to be paid
by the Client and (ii) at the Client's risk and expense, obtain any export
license or other official authorization necessary to export the Products. The
Client shall arrange for insurance and shall select the freight carrier used by
Patheon to ship Products and may monitor Patheon's shipping and freight
practices as they pertain to this Agreement. Products shall be transported in
accordance with the Specifications.

5.5  LATE SHIPMENT AND SHELF LIFE

          (a) Late Shipment. In the event that any Products are shipped to
Client more than 14 days after the agreed upon date (for reasons other than
Client's failure to deliver Active Material required to manufacture such
Products to Patheon within the time frames requested), the parties shall meet as
necessary in order to try to resolve the reasons, if any for the late shipment,
amicably. Should the parties fail to reach resolution under this Section 5.5,
then their dispute will be handled in accordance with Section 12.1 hereof.

          (b) The Product shall be delivered to Client or Client's designee as
set forth below ("DISTRIBUTION SHELF LIFE"):

<TABLE>
<CAPTION>
                             TRADE PRODUCT TO BE SHIPPED     SAMPLE PRODUCT TO BE SHIPPED TO
FDA- APPROVED SHELF LIFE   TO CLIENT OR CLIENT'S DESIGNEE:     CLIENT OR CLIENT'S DESIGNEE:
------------------------   -------------------------------   -------------------------------
<S>                        <C>                               <C>
12 months                  unless otherwise mutually         unless otherwise mutually
                           agreed in writing, for a period   agreed in writing, for a period
                           of [**] immediately following     of [**] immediately following
                           the Commencement Date, no more    the Commencement Date, no more
                           than [**] from the time of        than [**] from the time of
                           commencement of compounding of    commencement of compounding of
                           the Active Material with          the Active Material with
                           Components                        Components
</TABLE>

                                      -15-

<PAGE>

<TABLE>
<S>                        <C>                               <C>
18 months                  No more than [**] from the time   no more than [**] from the time
                           of commencement of compounding    of commencement of compounding
                           of the Active Material with       of the Active Material with
                           Components                        Components

24 months                  With at least [**] dating         With at least [**] dating
                           remaining                         remaining
</TABLE>

However, if this is not achievable due to an out-of-specification or significant
batch deviation investigation, then the parties agree to work together to
maximize the shelf life of a batch of Product, including the packaging of the
subject Product into samples, if possible. At all times, the parties agree to
use commercially reasonable efforts to achieve a maximum distribution shelf life
and, in order to do so, if requested by Client, Patheon will [**]. The Client
shall have the right to reject any shipment of Products (other than Products
that were the subject of an out-of-specification or significant batch deviation
investigation), having less than the Distribution Shelf Life in accordance with
Section 6.1(a) hereof.

     In order to ensure that Client has sufficient time to review the Batch
Documentation to correct any defects in such documentation and release the
Product for shipment pursuant to a shipment request from Client:

     (1) for trade Product, Patheon will use best efforts to deliver the
     documentation package as defined in the Quality Agreement by [**] from the
     start of compounding. Both parties agree to cooperate to resolve any
     documentation issues by [**]; and

     (2) for sample Product, Patheon will use best efforts to deliver the
     documentation package as defined in the Quality Agreement by [**] from the
     start of compounding. Both parties agree to cooperate to resolve any
     documentation issues by [**].

     (c) Initial Batches. Notwithstanding the provisions of Section 5.5(b),
above or, anything else contained in this Agreement to the contrary, Patheon
shall not be liable for the loss of Active Material required to replace the [**]
shipments of Product rejected by Client for failure to meet the Distribution
Shelf Life provided such batches were manufactured by Patheon in accordance with
the Specifications and cGMPs.

5.6  INVOICES AND PAYMENT.

          Except as otherwise provided in this Agreement, Patheon shall charge
the Client for the Manufacturing Services only in respect of those Products that
are shipped to Client and shall submit to the Client, at the same time as each
shipment of Product, an invoice covering such shipment. Invoices shall be sent
by courier to such address as may be provided by the Client in writing from time
to time. Patheon shall also submit to the Client, with each shipment

                                      -16-

<PAGE>

of Products, a duplicate copy of the invoice covering such shipment. Patheon
shall also provide the Client with an invoice covering any Inventory or
Components which are to be purchased by the Client pursuant to the terms of this
Agreement. Each such invoice shall, to the extent applicable, identify the
Client purchase order number, Product numbers, names and quantities, unit price,
freight charges and the total amount to be remitted by the Client. The Client
shall pay all such invoices within 30 days of the date thereof.

                                    ARTICLE 6

                           PRODUCT CLAIMS AND RECALLS

6.1  PRODUCT CLAIMS.

          (a) Product Claims. The Client or its designated agent has the right
to reject any portion of any shipment of Products that deviates from the
Specifications or cGMPs, without invalidating any remainder of such shipment.
The Client or its designated agent shall inspect the Products manufactured by
Patheon within a reasonable time after the receipt thereof, including Batch
Documentation, and shall give Patheon written notice (a "DEFICIENCY NOTICE") of
all claims for Products that deviate from the Specifications or cGMPs within 30
days after the Client's or its designated agent's receipt thereof (or, in the
case of any defects not reasonably susceptible to discovery upon receipt of the
Product, within 30 days after discovery thereof by the Client, but in no event
after the expiration date of the Product). Should the Client fail to provide
Patheon with written notice of its acceptance or rejection of the delivery
within 30 days of receipt of a delivery of Products including Batch
Documentation, then the delivery shall be deemed to have been accepted by the
Client on the 31st day after delivery. Except as set out in Section 6.2, Patheon
shall have no liability for any deviations for which it has not received notice
within the applicable 30-day period.

          (b) Determination of Deficiency. Upon receipt of a Deficiency Notice,
Patheon shall have 10 days to advise the Client by notice in writing that it
disagrees with the contents of such Deficiency Notice. If the Client and Patheon
fail to agree within 10 days after Patheon's notice to the Client as to whether
any Products identified in the Deficiency Notice deviate from the Specifications
or cGMPs, then the parties shall mutually select an independent laboratory to
evaluate if any of the Products deviate from the Specifications or cGMPs. Such
evaluation shall be binding on the parties, and if such evaluation certifies
that any Products deviate from the Specifications or cGMPs, the Client may
reject those Products in the manner contemplated in this Section 6.1. If such
evaluation does not so certify in respect of any such Products, then the Client
shall be deemed to have accepted delivery of such Products on the 40th day after
delivery.

          (c) Patheon Responsibility. In the event the Client rejects Products
in accordance with this Section 6.1 and the deviation is determined to arise
from Patheon's failure to provide the Manufacturing Services in accordance with
the Specifications and cGMPs, Patheon will credit the Client's account for
Patheon's invoice price to the Client for such defective Products.

                                      -17-

<PAGE>

If the Client shall have previously paid for such defective Products, Patheon
shall promptly, at the Client's election, either: (i) refund the invoice price
for such defective Products; (ii) offset such amount against other amounts due
to Patheon hereunder; or (iii) replace such Products with conforming Products
without the Client being liable for payment therefor under Section 3.1,
contingent upon the receipt from the Client of all Active Material required for
the manufacture of such replacement Products. Subject to the limitations set out
in Section 10.2, Patheon shall be responsible for paying for any Active Material
needed under this Section 6.1(c) in accordance with the procedures set forth in
Section 2.3 hereof. Further, if it is determined that there is a deviation with
any part of the shipment of Product, at the Client's option, Patheon will take
receipt of such shipment and perform an inspection of 100% of the Product in the
shipment. The parties acknowledge that time is of the essence in meeting their
obligations under this Section 6.1(c).

     (d) Shortages. Claims for shortages in the amount of Product shipped by
Patheon shall be dealt with as may reasonably be agreed to by the parties;
provided, however, in the event that a shipment of Product received by Client or
its designee is less than [**]% of the amount ordered by Client pursuant to
Section 5.1(b) hereof ("SHORTAGE AMOUNT"), upon receipt of written request by
Client, Patheon shall use commercially reasonable efforts to manufacture
additional Product to replace the Shortage Amount. In the event that such
Shortage Amount is less than a validated batch size, then Patheon shall
manufacture the next highest validated batch size of Product ("SHORTAGE BATCH")
and package such Shortage Batch in accordance with the Client's written
instructions, including the Shortage Amount. The fees to be paid by the Client
for the Shortage Amount shall be the same unit price as set forth in the invoice
covering the shipment that is the subject of the Product Claim. The fees to be
paid by the Client for the balance of the Shortage Batch, if any, shall be the
next lowest priced fees payable by bottle count as set forth in Schedule B
hereto.

6.2  PRODUCT RECALLS AND RETURNS.

     (a) Records and Notice. Patheon and the Client shall each maintain such
records as may be necessary to permit a Recall of any Products delivered to the
Client or customers of the Client. Each party shall promptly notify the other by
telephone (to be confirmed in writing) of any information which might affect the
marketability, safety or effectiveness of the Products and/or which might result
in the Recall or seizure of the Products. Upon receiving any such notice or upon
any such discovery, each party shall cease and desist from further shipments of
such Products in its possession or control until a decision has been made
whether a Recall or some other corrective action is necessary. The decision to
initiate a Recall or to take some other corrective action, if any, shall be made
and implemented by the Client. "RECALL" shall mean any action (i) by the Client
to recover title to or possession of quantities of the Products sold or shipped
to third parties (including, without limitation, the voluntary withdrawal of
Products from the market); or (ii) by any regulatory authorities to detain or
destroy any of the Products. Recall shall also include any action by either
party to refrain from selling or shipping quantities of the Products to third
parties which would have been subject to a Recall if sold or shipped.

                                      -18-

<PAGE>

     (b) Recalls. In the event (i) any governmental or regulatory authority
issues a directive, order or, following the issuance of a safety warning or
alert with respect to a Product, a written request that any Product be Recalled,
(ii) a court of competent jurisdiction orders such a Recall, or (iii) the Client
determines that any Product should be Recalled or that a "dear doctor" letter is
required relating the restrictions on the use of any Product, Patheon will
co-operate as reasonably required by the Client, having regard to all applicable
laws and regulations.

     (c) Product Returns. The Client or its designated agent shall have the
responsibility for handling customer returns of the Products. Patheon shall
provide the Client or its designated agent with such assistance as the Client
may reasonably require to handle such returns.

     (d) Patheon's Responsibility. To the extent that a Recall or return results
from, or arises out of, a failure by Patheon to provide the Manufacturing
Services in accordance with the Specifications and cGMPs, at Client's option,
Patheon shall be responsible for the documented out-of-pocket expenses of such
Recall or return and shall either (i) reimburse the Client for the price that
the Client paid to Patheon for manufacturing the Recalled Products or (ii) use
its commercially reasonable efforts to replace the Recalled or returned Products
with new Products at no charge to the Client, contingent upon the receipt from
the Client of all Active Material required for the manufacture of such
replacement Products. If Client elects to have the Recalled Product replaced,
subject to the limitations set out in Section 10.2, Patheon shall pay all costs
related to the Active Material required for the manufacture of replacement
Products in accordance with the procedures set forth in Section 2.3 hereof. In
all other circumstances, Recalls, returns or other corrective actions shall be
made at the Client's cost and expense. The parties acknowledge that time is of
the essence in meeting their obligations under this Section 6.2(d).

6.3  DISPOSITION OF DEFECTIVE OR RECALLED PRODUCTS.

          The Client shall not dispose of any damaged, defective, returned or
Recalled Products in relation to which it intends to assert a claim against
Patheon without Patheon's prior written authorization to do so. Alternatively,
Patheon may instruct the Client to return such Products to Patheon. Patheon
shall bear the cost of disposition with respect to any damaged, defective,
returned or Recalled Products in relation to which it bears responsibility under
Section 6.1 or 6.2 hereof. In all other circumstances, the Client shall bear the
cost of disposition with respect to any damaged, defective, returned or Recalled
Products.

6.4  CUSTOMER QUESTIONS AND COMPLAINTS.

          The Client or its designated agent shall have the full responsibility
for responding to questions and complaints from the Client's customers.
Questions or complaints received by Patheon from the Client's customers shall be
promptly referred to the Client. Patheon shall co-operate as reasonably required
to allow the Client to determine the cause of and resolve any customer questions
and complaints. Such assistance shall include follow-up investigations,

                                      -19-

<PAGE>

including testing. In addition, within 10 days from the date of request, Patheon
shall provide the Client with all necessary information that will enable the
Client to respond properly to questions or complaints relating to the Products.
Unless it is determined that the cause of any customer complaint resulted from a
failure by Patheon to provide the Manufacturing Services in accordance with the
Specifications and cGMPs, all costs incurred in respect of this Section 6.4
shall be borne by the Client.

6.5  SOLE REMEDY.

          Except for the indemnity provided in Section 10.3 and subject to the
limitations set forth in Sections 10.1 and 10.2, the remedies described in this
Article 6 shall be the Client's sole remedy for any failure by Patheon to
provide the Manufacturing Services in accordance with the Specifications and
cGMPs.

                                    ARTICLE 7

                                  CO-OPERATION

7.1  QUARTERLY REVIEW.

          Each party shall forthwith upon execution of this Agreement appoint
one of its employees to be a relationship manager responsible for liaison
between the parties. The relationship managers shall meet not less than
quarterly to review the current status of the business relationship and manage
any issues that have arisen.

7.2  GOVERNMENTAL AGENCIES.

          Subject to Section 7.7, each party may communicate with any
governmental agency, including but not limited to governmental agencies
responsible for granting regulatory approval for the Products, regarding such
Products if in the opinion of that party's counsel, such communication is
necessary to comply with the terms of this Agreement or the requirements of any
law, governmental order or regulation; provided, however, that unless in the
reasonable opinion of its counsel there is a legal prohibition against doing so,
such party shall permit the other party to accompany and take part in any
communications with the agency, and to receive copies of all such communications
to and/or from the agency.

7.3  RECORDS AND ACCOUNTING BY PATHEON.

          Patheon shall keep records of the manufacture, testing and shipping of
the Products, Components and Active Material, and retain samples of such
Products, Components and Active Material as are necessary to comply with
manufacturing regulatory requirements applicable to Patheon, as well as to
assist with resolving Product complaints and other similar

                                      -20-

<PAGE>

investigations. Copies of such records and samples shall be retained for a
period of one year following the date of Product expiry, or longer if required
by law or the Quality Agreement. Patheon is responsible for retaining samples of
the Products, Components and Active Material either that are necessary to comply
with the legal/regulatory requirements applicable to the Client or that are
requested by the Client. For the avoidance of doubt, if a Component or Active
Material is used in more than one batch of Product, Patheon shall retain the
necessary samples for a period of one year following the date of Product expiry,
or longer if required by law, for the final batch of Product made with such
Component or Active Material. Prior to destroying any records or retained
samples under this Section 7.3, Patheon shall notify the Client and the Client
shall have the option of having such records or retained samples sent to a
location of the Client's choice at the Client's expense.

7.4  INSPECTION.

          The Client may inspect Patheon reports and records relating to this
Agreement during normal business hours and with reasonable advance notice. A
Patheon representative shall be present during any such inspection.

7.5  ACCESS.

          Patheon shall provide the Client with reasonable access at mutually
agreeable times to any of its facilities in which the Products are manufactured,
stored, handled or shipped in order to permit the Client's verification of
Patheon's compliance with the Patheon Manufacturing Responsibilities and with
all applicable laws and regulations. For greater certainty, the right of access
provided in this Section 7.5 shall not include a right to access or inspect
Patheon's financial records. Patheon shall notify the Client of any inspections
by any governmental agency directly or indirectly involving the Products.

7.6  REPORTS.

          Patheon will supply all Product data, including release test results,
complaint test results, all investigations (in manufacturing, testing and
storage), and the like, that the Client reasonably requires in order to complete
any filing under any applicable regulatory regime, including any annual product
report information that the Client is required to file with the FDA, thirty (30)
days prior to the due date for such report or filing. At the Client's request
and subject to an additional fee to be agreed by the parties, Patheon may
prepare annual product review information on behalf of the Client and in
accordance with the Client's instructions.

7.7  FDA FILINGS

     (a) FDA Filings. The Client shall have the sole responsibility for filing
all documents with the FDA and taking any other actions that may be required to
maintain FDA Approval for the commercial manufacture of all of the Products.
Patheon shall assist the Client, to the extent consistent with Patheon's
obligations under this Agreement. Client shall provide Patheon with

                                      -21-

<PAGE>

copies of all FDA filings at the time of submission which contain chemistry,
manufacturing and controls (CMC) information regarding the Product.

     (b) Verification of Data. Prior to filing any documents with the FDA that
incorporate data generated by Patheon that has a material change to such data
made by Client, the Client shall provide Patheon with a copy of the documents
incorporating such data so as to give Patheon the opportunity to verify the
accuracy and regulatory validity of such documents as they relate to the Patheon
generated data. The standard review period is 30 days, however shorter times
shall be satisfactory upon agreement of the parties.

     (c) Client Responsibility. For clarity, the parties agree that in reviewing
the documents referred to in paragraph (b) above, Patheon's role will be limited
to verifying the accuracy of the description of the work undertaken or to be
undertaken by Patheon. As such, Patheon shall not assume any responsibility for
the accuracy of the NDA or the ANDA, as the case may be. The sole responsibility
of the preparation and filing of the NDA or the ANDA shall be borne by the
Client.

                                      -22-

<PAGE>

7.8  TECHNOLOGY TRANSFERS.

          Provided that the Client is not then in breach of its obligations
under this Agreement, Patheon shall, at the Client's expense, provide such
assistance as is reasonably necessary to assist the Client in transferring the
manufacture of Product to another facility including manufacturing processes and
analytical methods; provided, however, no competitor of Patheon shall be
permitted to have access to the Manufacturing Site.

                                    ARTICLE 8

                              TERM AND TERMINATION

8.1  INITIAL TERM.

          This Agreement shall become effective as of the Effective Date and
shall continue for a period of three Years from the Commencement Date (the
"INITIAL TERM"), unless terminated earlier by one of the parties in accordance
herewith. This Agreement shall automatically continue after the Initial Term for
successive terms of one year each unless terminated earlier pursuant to Sections
8.2, 8.3 or 8.4.

8.2  TERMINATION BY PATHEON OR CLIENT.

          Either party shall have the right to terminate this Agreement for any
reason upon the giving of written notice to the other party at least 12 months,
on the part of the Client, or at least 18 months, on the part of Patheon, prior
the end of the then current term.

8.3  TERMINATION FOR CAUSE.

     (a) Either party at its sole option may terminate this Agreement upon
written notice in circumstances where the other party has failed to remedy a
material breach of any of its representations, warranties or other obligations
under this Agreement within 60 days following receipt of a written notice (the
"REMEDIATION PERIOD") of said breach that expressly states that it is a notice
under this Section 8.3(a) (a "BREACH NOTICE").

     (b) Either party, at its sole option, may immediately terminate this
Agreement upon written notice, but without prior advance notice, to the other
party in the event that: (i) the other party is declared insolvent or bankrupt
by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is
filed in any court of competent jurisdiction by such other party; or (iii) this
Agreement is assigned by such other party for the benefit of creditors.

                                      -23-

<PAGE>

     (c) The Client may terminate this Agreement as to any Product upon 30 days'
prior written notice in the event that any governmental agency takes any action,
or raises any objection, that prevents the Client from importing, exporting,
purchasing or selling such Product.

     (d) Patheon may terminate this Agreement upon six months' prior written
notice if the Client assigns pursuant to Section 13.6 any of its rights under
this Agreement to an assignee other than a purchaser or merger partner that, in
the opinion of Patheon acting reasonably, is: (i) not a credit worthy substitute
for the Client; or (ii) a competitor of Patheon; or (iii) an entity with whom
Patheon has had prior unsatisfactory business relations.

8.4  PRODUCT DISCONTINUATION.

          The Client shall provide at least six months' advance notice if it
intends to no longer order a Product due to that Product's discontinuance in the
market. The Client shall not be obliged to purchase any Product other than that
made by Patheon pursuant to Firm Orders that have been submitted by the date of
the notice given above. In the event that the Client does not want any
additional Product made, the Client shall pay to Patheon (1) an amount equal to
75% of the fees for the first month of the then current Firm Order and, (2) an
amount equal to 50% of the fees for the second and third months of the then
current Firm Order by the Client for such Product.

8.5  OBLIGATIONS ON TERMINATION.

          If this Agreement expires or is terminated in whole or in part for any
reason, then (in addition to any other remedies Patheon may have in the event of
default by the Client):

     (a)  the Client shall take delivery of and pay for all undelivered Products
          that are manufactured and/or packaged pursuant to a Firm Order, at the
          price in effect at the time the Firm Order was placed;

     (b)  the Client shall purchase, at Patheon's cost (including all costs
          incurred by Patheon in connection with the purchase and handling of
          such Inventory), the Inventory applicable to the Products which was
          purchased, produced or maintained by Patheon in contemplation of
          filling Firm Orders or in accordance with Section 5.2 prior to notice
          of termination being given;

     (c)  the Client shall satisfy the purchase price payable pursuant to
          Patheon's orders with suppliers of Components, provided such orders
          were made by Patheon in reliance on Firm Orders or in accordance with
          Section 5.2;

     (d)  Patheon shall return to the Client all unused Active Material (with
          shipping and related expenses, if any, to be borne by the Client) as
          well as all Inventory and Components for which the Client has paid
          pursuant to Sections 8.5 (b) and (c);

                                      -24-

<PAGE>

     (e)  Patheon shall return any and all documentation related to the Product
          to Client.

Any termination or expiration of this Agreement shall not affect any outstanding
obligations or payments due hereunder prior to such termination or expiration,
nor shall it prejudice any other remedies that the parties may have under this
Agreement. For greater certainty, termination of this Agreement for any reason
shall not affect the obligations and responsibilities of the parties pursuant to
Articles 8, 10 and 11 and Sections 6.2, 6.3, 6.4, 7.3, 7.8, 13.1, 13.2, 13.3 and
13.15, all of which survive any termination.

                                    ARTICLE 9

                    REPRESENTATIONS, WARRANTIES AND COVENANTS

9.1  AUTHORITY.

          Each party covenants, represents and warrants that it has the full
right and authority to enter into this Agreement, and that it is not aware of
any impediment that would inhibit its ability to perform its obligations
hereunder.

9.2  NON-INFRINGEMENT.

          The Client covenants, represents and warrants that, as of the
Effective Date:

     (a)  the Specifications for each of the Products are its or its Affiliate's
          property and that the Client may lawfully disclose the Specifications
          to Patheon;

     (b)  to the best of its' knowledge, any Intellectual Property, other than
          Patheon Intellectual Property, utilized by Patheon in connection with
          the provision of the Manufacturing Services according to the
          Specifications (i) is owned or licensed by the Client or its
          Affiliate; (ii) may be lawfully used as directed by the Client; and,
          (iii) such use does not infringe and will not infringe and Third Party
          Rights;

     (c)  to the best of its' knowledge, there are no actions or other legal
          proceedings, the subject of which is the infringement of Third Party
          Rights related to any of the Specifications, or any of the Active
          Material and the Components, or the sale, use or other disposition of
          any Product made in accordance with the Specifications;

     (d)  the Specifications for all Products conforms to all applicable cGMPs;
          and,

     (e)  the Products, if labelled and manufactured in accordance with the
          Specifications and in compliance with applicable cGMPs (i) may be used
          in clinical trials and/or lawfully sold and distributed in every
          jurisdiction in which the Client markets such Products; and (ii) will
          be safe for human consumption.

                                      -25-

<PAGE>

9.3  DEBARRED PERSONS.

          Patheon covenants that it will not in the performance of its
obligations under this Agreement use the services of any person debarred or
suspended under 21 U.S.C. Section 335(a) or (b). Patheon represents that it does
not currently have, and covenants that it will not hire, as an officer or an
employee any person who has been convicted of a felony under the laws of the
United States for conduct relating to the regulation of any drug product under
the United States Food, Drug and Cosmetic Act.

9.4  PERMITS.

          The Client shall be solely responsible for obtaining or maintaining,
on a timely basis, any permits or other regulatory approvals in respect of the
Products or the Specifications, including, without limitation, all marketing and
post-marketing approvals.

9.5  COMPLIANCE WITH LAWS.

          Each party, in connection with its performance under this Agreement,
shall comply with all applicable laws, rules, regulations and orders.

9.6  NO WARRANTY.

          PATHEON MAKES NO WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, BY
FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. PATHEON
MAKES NO WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE OR WARRANTY OF
MERCHANTABILITY.

                                   ARTICLE 10

                            REMEDIES AND INDEMNITIES

10.1 CONSEQUENTIAL DAMAGES.

          Under no circumstances whatsoever shall either party be liable to the
other in contract, tort, negligence, breach of statutory duty or otherwise for
any (direct or indirect) loss of profits, of production, of anticipated savings,
of business or goodwill or for any liability, damage, costs or expense of any
kind incurred by the other party of an indirect or consequential nature.

                                      -26-

<PAGE>

10.2 LIMITATION OF LIABILITY.

     (a) Active Material. Except as expressly set forth in Section 2.3 hereof,
Patheon shall not be responsible for any loss or damage to the Active Material.

     (b) Products. Except in circumstances where Patheon has failed to provide
the Manufacturing Services in accordance with the Specifications and cGMPs,
Patheon shall not be liable nor have any responsibility for any deficiencies in,
or other liabilities associated with, any Product manufactured by it, including,
without limitation, any deficiencies with respect to the Specifications, the
safety, efficacy or marketability of the Products or any distribution thereof.

     (c) Maximum Liability. Patheon's maximum liability under this Agreement for
any reason other than personal injury, including, without limitation, any
liability arising under Article 6 (other than a liability for loss of Active
Material) or Section 10.3 hereof or resulting from a breach of its
representations, warranties or other obligations under this Agreement shall not
exceed (i) for Firm Orders made pursuant to Section 5.1 of less than [**]
tablets per Year, up to the amount of $500,0000; (ii) for Firm Orders of between
[**] to [**] tablets per Year, up to the amount of $750,000; or (iii) for Firm
Orders of greater than [**] tablets per Year, up to the amount of $1,000,000, in
the aggregate for each Year of this Agreement.

10.3 PATHEON.

          Subject to Sections 10.1 and 10.2, Patheon agrees to defend, indemnify
and hold the Client, its officers, employees and agents harmless against any and
all losses, damages, costs, claims, demands, judgments and liability to, from
and in favour of third parties (other than Affiliates) resulting from, or
relating to any claim of personal injury or property damage to the extent that
such injury or damage is the result of a failure by Patheon to provide the
Manufacturing Services in accordance with the Specifications and cGMPs except to
the extent that any such losses, damages, costs, claims, demands, judgments and
liability are due to the negligence or wrongful act(s) of the Client, its
officers, employees or agents or Affiliates.

          In the event of a claim, the Client shall: (a) promptly notify Patheon
of any such claim; (b) use commercially reasonable efforts to mitigate the
effects of such claim: (c) reasonably cooperate with Patheon in the defence of
such claim; (d) permit Patheon to control the defence and settlement of such
claim, all at Patheon's cost and expense.

10.4 CLIENT.

          Subject to Sections 10.1 and 10.2, the Client agrees to defend,
indemnify and hold Patheon, its officers, employees and agents harmless against
any and all losses, damages, costs, claims, demands, judgments and liability to,
from and in favour of third parties (other than Affiliates) resulting from, or
relating to any claim of infringement or alleged infringement of any Third Party
Rights in respect of the Products, and any claim of personal injury or property
damage to the extent that such injury or damage is the result of a breach of
this Agreement by the

                                      -27-

<PAGE>

Client, including, without limitation, any representation or warranty contained
herein, except to the extent that any such losses, damages, costs, claims,
demands, judgments and liability are due to the negligence or wrongful act(s) of
Patheon, its officers, employees or agents.

          In the event of a claim, Patheon shall: (a) promptly notify the Client
of any such claims; (b) use commercially reasonable efforts to mitigate the
effects of such claim; (c) reasonably cooperate with the Client in the defence
of such claim; (d) permit the Client to control the defence and settlement of
such claim, all at the Client's cost and expense.

                                   ARTICLE 11

                                 CONFIDENTIALITY

          11.1 The parties agree that the provisions of the Confidentiality
Agreement shall apply to all confidential information disclosed by the parties
under this Agreement, which agreement remains in effect in accordance with its
terms; provided, however, that in the event the Confidentiality Agreement
expires or is terminated prior to the expiration or termination of this
Agreement, the terms of the Confidentiality Agreement shall continue to govern
the parties' obligations of confidentiality with respect to any confidential or
proprietary information disclosed by the parties hereunder, for the term of this
Agreement, as though such agreement remained in full force and effect.

          11.2 Notwithstanding anything to the contrary in this Agreement,
nothing shall prohibit a party from making such disclosures to the extent deemed
necessary under applicable federal or state securities laws or any rule or
regulation of any nationally recognized securities exchange; in such event,
however, the disclosing Party shall use good faith efforts to obtain
confidential treatment to the extent available.

          11.3 Patheon acknowledges and agrees that (i) Client is a
publicly-held company and (ii) Patheon is aware and has advised its employees,
directors, officers and agents involved in the evaluation and negotiation of the
transaction contemplated by this Agreement that applicable securities laws
prohibit any person who is aware of material, non-public information about a
company obtained directly or indirectly from that company from purchasing or
selling securities of such company or from communicating such information to any
other person under circumstances in which it is reasonably foreseeable that such
person is likely to purchase or sell such securities. Client will provide
Patheon with advance written notice of its intent to make such a disclosure and
will provide Patheon with the opportunity to comment on any confidential
treatment requested prior to the submission.

                                      -28-

<PAGE>

                                   ARTICLE 12

                               DISPUTE RESOLUTION

12.1 COMMERCIAL DISPUTES.

          In the event of any dispute arising out of or in connection with this
Agreement (other than a dispute determined in accordance with Section 6.1(b) or
a Technical Dispute), the parties shall first try to solve it amicably. In this
regard, any party may send a notice of dispute to the other, and each party
shall appoint, within 10 Business Days from receipt of such notice of dispute, a
single representative having full power and authority to solve the dispute. The
representatives so designated shall meet as necessary in order to solve such
dispute. If these representatives fail to solve the matter within one month from
their appointment, or if a party fails to appoint a representative within the 10
Business Day period set forth above, such dispute shall immediately be referred
to the Chief Operating Officer or Executive Vice President, Operations (or such
other officer as they may designate) of each party who will meet and discuss as
necessary in order to try to solve the dispute amicably. Should the parties fail
to reach a resolution under this Section 12.1, their dispute will be referred to
a court of competent jurisdiction in accordance with Section 13.15.

12.2 TECHNICAL DISPUTE RESOLUTION.

          In the event of a dispute (other than disputes in relation to the
matters set out in Sections 6.1(b) and 12.1) between the parties that is
exclusively related to technical aspects of the manufacturing, packaging,
labelling, quality control testing, handling, storage or other activities under
this Agreement (a "TECHNICAL DISPUTE"), the parties shall make all reasonable
efforts to resolve the dispute by amicable negotiations. In this regard, senior
representatives of each party shall, as soon as practicable and in any event no
later than 10 Business Days after a written request from either party to the
other, meet in good faith to resolve any Technical Dispute. If, despite such
meeting, the parties are unable to resolve a Technical Dispute within a
reasonable time, and in any event within 30 Business Days of such written
request, the Technical Dispute shall, at the request of either party, be
referred for determination to an expert in accordance with the provisions of
Schedule F. In the event that the parties cannot agree whether a dispute is a
Technical Dispute, Section 12.1 shall prevail. For greater certainty, the
parties agree that the release of the Products for sale or distribution pursuant
to the applicable marketing approval for such Products shall not by itself
indicate compliance by Patheon with its obligations in respect of the
Manufacturing Services and further that nothing in this Agreement (including
Schedule F) shall remove or limit the authority of the relevant qualified person
(as specified by the Quality Agreement) to determine whether the Products are to
be released for sale or distribution.

                                      -29-

<PAGE>

                                   ARTICLE 13

                                  MISCELLANEOUS

13.1 INVENTIONS.

     (a) For the term of this Agreement, Client hereby grants to Patheon a
non-exclusive, paid-up, royalty-free, non-transferable license of Client's
Intellectual Property which Patheon must use in order to perform the
Manufacturing Services.

     (b) All Intellectual Property generated or derived by Patheon in the course
of performing the Manufacturing Services, to the extent it is specific to the
development, manufacture, use and sale of the Client's Product that is the
subject of the Manufacturing Services, shall be the exclusive property of the
Client.

     (c) All Intellectual Property generated or derived by Patheon in the course
of performing the Manufacturing Services which are not specific, or dependent
upon, Client's Product and which have application to manufacturing processes or
formulation development of drug products or drug delivery systems shall be the
exclusive property of Patheon (the "Broader Intellectual Property Rights").
Patheon hereby grants to Client, a non-exclusive, paid-up, royalty-free,
transferable license of Patheon's Broader Intellectual Property Rights which
Client may use for the manufacture of Client's Product.

     (d) Each party shall be solely responsible for the costs of filing,
prosecution and maintenance of patents and patent applications on its own
Inventions.

     (e) Either party shall give the other party written notice, as promptly as
practicable, of all Inventions which can reasonably be deemed to constitute
improvements or other modifications of the Products or processes or technology
owned or other wise controlled by such party. Inventions owned by Patheon in
accordance herewith shall only be utilized by Patheon in connection with the
provision of the Manufacturing Services with the Client's prior written consent.

                                      -30-

<PAGE>

13.2 INTELLECTUAL PROPERTY.

          Subject to Section 13.1, all Intellectual Property of the Client shall
be owned by the Client and all Intellectual Property of Patheon shall be owned
by Patheon. The Client and Patheon hereby acknowledge that neither party has,
nor shall it acquire, any interest in any of the other party's Intellectual
Property unless otherwise expressly agreed to in writing. Each party agrees not
to use any Intellectual Property of the other party, except as specifically
authorized by the other party or as required for the performance of its
obligations under this Agreement.

13.3 INSURANCE.

          Each party shall use commercially reasonable efforts to maintain
commercial general liability insurance covering the obligations of that party
under this Agreement through the term of this Agreement and for a period of
three years thereafter, which insurance shall afford limits of not less than
$5,000,000 for each occurrence of products liability and property damage
liability. If requested each party will provide the other with a certificate of
insurance evidencing the above and showing the name of the issuing company, the
policy number, the effective date, the expiration date and the limits of
liability. The insurance certificate shall further provide for a minimum of 30
days' written notice to the insured of a cancellation of, or a material change
in, the insurance. If a party is unable to maintain the insurance policies
required under this Agreement through no fault on the part of such party, then
such party shall forthwith notify the other party in writing and the parties
shall in good faith negotiate appropriate amendments to the insurance provision
of this Agreement in order to provide adequate assurances.

13.4 INDEPENDENT CONTRACTORS.

          The parties are independent contractors and this Agreement shall not
be construed to create between Patheon and the Client any other relationship
such as, by way of example only, that of employer-employee, principal agent,
joint-venturer, co-partners or any similar relationship, the existence of which
is expressly denied by the parties hereto.

13.5 NO WAIVER.

          Either party's failure to require the other party to comply with any
provision of this Agreement shall not be deemed a waiver of such provision or
any other provision of this Agreement.

13.6 ASSIGNMENT.

          Patheon may not assign this Agreement or any of its rights or
obligations hereunder except with the written consent of the Client, such
consent not to be unreasonably withheld. For greater certainty, Patheon may
arrange for subcontractors to perform specific services arising under this
Agreement provided that Patheon remains responsible to the Client

                                      -31-

<PAGE>

under this Agreement. Subject to Section 8.2(d), the Client may assign this
Agreement or any of its rights or obligations hereunder without approval from
Patheon; provided, however, that the Client shall give prior written notice of
any assignment to Patheon, any assignee shall covenant in writing with Patheon
to be bound by the terms of this Agreement and the Client shall remain liable
hereunder. Notwithstanding the foregoing provisions of this Section 13.6, either
party may assign this Agreement to any of its Affiliates or to a successor to or
purchaser of all or substantially all of its business, provided that such
assignee executes an agreement with the non-assigning party hereto whereby it
agrees to be bound hereunder.

13.7 FORCE MAJEURE.

          Neither party shall be liable for the failure to perform its
obligations under this Agreement if such failure is occasioned by a cause or
contingency beyond such party's reasonable control, including, but not limited
to, strikes or other labour disturbances, lockouts, riots, wars, acts of
terrorism, fires, floods, storms, inability to obtain fuel, power, or components
or compliance with any order or regulation of any government entity acting
within colour of right (a "Force Majeure Event"). A party claiming a right to be
excused performance under this Section 13.7 shall immediately notify the other
party in writing of the extent of its inability to perform, which notice shall
specify the occurrence beyond its reasonable control that prevents such
performance. Neither party shall be entitled to rely on a Force Majeure Event to
relieve it from an obligation to pay money (including any interest for delayed
payment) which would otherwise be due and payable under this Agreement.

13.8 ADDITIONAL PRODUCT.

          Additional products may be added to this Agreement and such additional
products shall be governed by the general conditions hereof with any special
terms (including, without limitation, price) governed by an addendum hereto.

13.9 NOTICES.

          Any notice, approval, instruction or other written communication
required or permitted hereunder shall be sufficient if made or given to the
other party by personal delivery, by telecopier or facsimile communication or by
sending the same by first class mail, postage prepaid to the mailing address, or
telecopier or facsimile number set forth below:

          If to the Client:

          Critical Therapeutics, Inc.
          60 Westview Street
          Lexington, MA  02421

                                      -32-

<PAGE>

          Attention: Chief Operating Officer

          Telecopier No.: (781) 862-5691

          If to Patheon:

          Patheon Pharmaceuticals Inc.
          c/o Patheon Inc.
          7070 Mississauga Road
          Mississauga, Ontario L5N 7J8
          Canada.

          Attention: President, Patheon North America

          Telecopier No.: (905) 812-6705

          With a copy to:

          Patheon Pharmaceuticals Inc.
          2110 East Galbraith Road
          Cincinnati, Ohio 45237
          U.S.A.

          Attention: Director of Legal Services

          Telecopier No. (513) 948-6927

or to such other addresses or telecopier or facsimile numbers provided to the
other party in accordance with the terms of this Section 13.9. Notices or
written communications made or given by personal delivery or by telecopier or
facsimile shall be deemed to have been sufficiently made or given when sent
(receipt acknowledged), or if mailed, five days after being deposited in the
United States or Canadian mail, postage prepaid or upon receipt, whichever is
sooner.

13.10 SEVERABILITY.

          If any provision of this Agreement is determined by a court of
competent jurisdiction to be invalid, illegal or unenforceable in any respect,
such determination shall not impair or affect the validity, legality or
enforceability of the remaining provisions hereof, and each provision is hereby
declared to be separate, severable and distinct.

                                      -33-

<PAGE>

13.11 ENTIRE AGREEMENT.

          This Agreement, together with the Quality Agreement and the
Confidentiality Agreement, constitutes the full, complete, final and integrated
agreement between the parties hereto relating to the subject matter hereof and
supersedes all previous written or oral negotiations, commitments, agreements,
transactions or understandings with respect to the subject matter hereof
including the Patheon Proposal #: CTI-FCO1-1100-0604-R1. Any modification,
amendment or supplement to this Agreement must be in writing and signed by
authorized representatives of both parties. In case of conflict, the prevailing
order of documents shall be this Agreement, the Quality Agreement and the
Confidentiality Agreement.

13.12 OTHER TERMS.

          The parties agree that no terms, provisions or conditions of any
purchase order or other business form or written authorization used by the
Client or Patheon will have any effect on the rights, duties or obligations of
the parties under or otherwise modify this Agreement, regardless of any failure
of the Client or Patheon to object to such terms, provisions, or conditions
unless such document specifically refers to this Agreement and is signed by both
parties.

13.13 NO THIRD PARTY BENEFIT OR RIGHT.

          For greater certainty, nothing in this Agreement shall confer or be
construed as conferring on any third party any benefit or the right to enforce
any express or implied term of this Agreement.

13.14 EXECUTION IN COUNTERPARTS.

          This Agreement may be executed in two counterparts, by original or
facsimile signature, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

                                      -34-

<PAGE>

13.15 GOVERNING LAW.

          This Agreement shall be construed and enforced in accordance with the
laws of the State of Delaware applicable therein. The parties expressly agree
that the UN Convention on Contracts for the International Sale of Goods shall
not apply to this Agreement.

          IN WITNESS WHEREOF, the duly authorized representatives of the parties
have executed this Agreement as of the date first written above.

                                        PATHEON PHARMACEUTICALS INC.

                                        by /s/ Clive Bennett
                                           -------------------------------------
                                        Name: Clive Bennett
                                        Title: President, Patheon North America

                                        CRITICAL THERAPEUTICS, INC.

                                        by /s/ Trevor Phillips
                                           -------------------------------------
                                        Name: Trevor Phillips
                                        Title: Chief Operating Officer

                                      -35-

<PAGE>

                                                      FINAL VERSION 22 JUNE 2005

                                   SCHEDULE A

PROCEDURE FOR SHIPMENT AND ACCEPTANCE OF PRODUCT SPECIFICATIONS AND TEST METHODS

Prior to commencement of commercial manufacturing of Product (not including
validation or other manufacturing that may be deemed commercial later) under
this Agreement the Client shall provide Patheon with authorized copies of the
Specifications from the sNDA filed by Client with the FDA. If the Specifications
provided are subsequently amended, then the Client shall provide Patheon with
revised and authorized copies of such revised Specifications. Upon acceptance of
the revised Specifications, Patheon shall provide Client with a signed and dated
receipt evidencing such acceptance of the revised Specifications by Patheon.

<PAGE>

                                   SCHEDULE B

              MINIMUM RUN QUANTITY, MINIMUM ANNUAL VOLUME AND FEES

PRICING TABLES - 2005 VOLUMES & 527 KG BATCH SIZE

<TABLE>
<CAPTION>
Package Format                         120'S BOTTLES
--------------                  ---------------------------
<S>                             <C>        <C>  <C>    <C>
Minimum Annual Volume (units)              [**]
Pkg Split (batch)                   [**]        [**]   [**]
Minimum Run Quantity (units)        [**]        [**]   [**]
Minimum Run Quantity (batch)        [**]        [**]   [**]
PRICE PER UNIT, IN USD              [**]        [**]   [**]
</TABLE>

<TABLE>
<CAPTION>
Package Format                  500'S BOTTLES
--------------                  -------------
<S>                             <C>
Minimum Annual Volume (units)       [**]
Pkg Split (batch)                   [**]
Minimum Run Quantity (units)        [**]
Minimum Run Quantity (batch)        [**]
PRICE PER UNIT, IN USD              [**]
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
Package Format                          20'S BOTTLES
--------------                  ---------------------------
<S>                             <C>        <C>  <C>    <C>
Minimum Annual Volume (units)              [**]
Pkg Split (batch)                   [**]        [**]   [**]
Minimum Run Quantity (units)        [**]        [**]   [**]
Minimum Run Quantity (batch)        [**]        [**]   [**]
PRICE PER UNIT, IN USD              [**]        [**]   [**]
</TABLE>

<TABLE>
<CAPTION>
PACKAGE FORMAT                   BULK TABLETS
--------------                  -------------
<S>                             <C>
Minimum Run Quantity (1000's)       [**]
Minimum Run Quantity (batch)        [**]
PRICE PER 1000, IN USD              [**]
</TABLE>

MANUFACTURING ASSUMPTIONS

1.   The manufacturing process at Patheon will closely follow the process
     information provided by Client.

2.   The API, Zileuton, has been evaluated as a Toxicity Category 2 compound.

3.   The manufacturing equipment train will consist of the following equipment:

                                      -2-

<PAGE>

     -    1,200L Gral Mixer

     -    T8 Aeromatic Fluid Bed Dryer

     -    Fitzmill

     -    Sweco

     -    30 CF V-Blender

     -    Fette Rotary Tablet Press, equipped with D-tooling

     -    48" Accela Cota

4.   A final batch size of 527 Kg, composed of two granulation loads has been
     decided.

5.   The two granulation loads will be blended in the 30 CF V-Blender.

6.   The target compressed tablet weight is 1,200 mg.

7.   Metal detection and dedusting will be done on-line following compression.

8.   Coating will be performed in the 48" Accela-Cota, in four pan loads.

9.   The coated tablet weight will be approximately 1,249 mg, resulting in a
     weight gain of 4%.

10.  Patheon assumes that the current cleaning procedure is adequate and full
     cleaning occurs after each run.

11.  A single batch manufacturing run is assumed.

                                      -3-

<PAGE>

PACKAGING ASSUMPTIONS

1.   The packaging equipment train will consist of the following equipment:

<TABLE>
<CAPTION>
120's Bottles                          500's Bottles
-------------                          -------------
<S>                                    <C>
-    Omega Bottle Unscrambler/blower   -    Bottle Blower (for hand fed bottles)

-    Cremer Tablet Filler              -    Kalish Monoblock Filler

-    Cottoner                          -    Cottoner

-    Capper                            -    Capper

-    Induction Sealer                  -    Induction Sealer

-    Re-torquer                        -    Re-torquer

-    Harland-Mercury Labeller          -    Kalish Labeller

-    Theile Outsert Applicator         -    MGS Outsert Applicator
</TABLE>

<TABLE>
<CAPTION>
20's Bottles
------------
<S>  <C>
-    Bottle Blower (for hand fed bottles)

-    Cremer Tablet Filler

-    Cottoner

-    Capper

-    Induction Sealer

-    Re-torquer

-    Sancoa Labeller

-    Theile Outsert Applicator
</TABLE>

2.   The packaging configuration will be as follows:

<TABLE>
<CAPTION>
120's, 500's and 20's Bottles
-----------------------------
<S>  <C>
-    120, 500 or 20 tablets per bottle

-    1 cap, with induction seal, per bottle

-    1 desiccant per bottle

-    1 label per bottle

-    1 outsert per bottle

-    12 bottles per shipper
</TABLE>

                                      -4-

<PAGE>

<TABLE>
<S>  <C>
-    1 shipper label per shipper
</TABLE>

3.   The cartons will also be coded with the lot number and expiry date.

4.   As requested by the Client, in addition to the full batch pricing, two
     split options: 50/50 and 25/75 between the 20's and 120's bottles are also
     presented.

5.   Bulk tablets will be packed into poly-lined sealed drums, based on in-house
     standard bulk packing procedure.

                                      -5-

<PAGE>

                                   SCHEDULE C

                                STABILITY TESTING

Patheon shall conduct stability testing in connection with the Products as
outlined in the sNDA filed by Client with the FDA which specifies the commercial
and Product stability protocols applicable to the stability testing and the fees
payable by the Client in connection with such testing. Such protocols shall be
subject to the approval of the FDA.

<PAGE>

                                   SCHEDULE D

              ACTIVE MATERIAL & ACTIVE MATERIAL REIMBURSEMENT VALUE

For the purposes of the Agreement, the parties agree that the Active Material
Reimbursement Value shall be as follows:

<TABLE>
<CAPTION>
                              ACTIVE MATERIAL
PRODUCT   ACTIVE MATERIAL   REIMBURSEMENT VALUE
-------   ---------------   -------------------
<S>       <C>               <C>
Zyflo     Zileuton          $[**]/kg.
</TABLE>

MAXIMUM REIMBURSEMENT VALUE

Patheon's liability for Active Material calculated in accordance with Section
2.3 of the Agreement for any Product in a Year shall not exceed, in the
aggregate, the maximum reimbursement value set forth below:

<TABLE>
<CAPTION>
PRODUCT   MAXIMUM REIMBURSEMENT VALUE
-------   ---------------------------
<S>       <C>
Zyflo     (a)  Up to the amount of $[**], in the aggregate for the first Year of
               this Agreement or

          (b)  For each of the second and subsequent Years of this Agreement, an
               amount of up to $[**] per Year, in the aggregate.
</TABLE>

<PAGE>

                                   SCHEDULE E

                       BATCH NUMBERING & EXPIRATION DATES

Each batch of the Product manufactured by Patheon will bear a unique lot number
using the Patheon batch numbering system. This number will appear on all
documents relating to the particular batch of the Product.

Based on the FDA's approved expiration period for the Product which may change
over time, Patheon will calculate the expiration date for each batch of the
Product by adding the expiration period of the Product supplied by the Client to
the Date of Manufacture of each batch. Such expiration date shall be written in
the format: Month/Year.

<PAGE>

                                   SCHEDULE F

                          TECHNICAL DISPUTE RESOLUTION

          Technical Disputes which cannot be resolved by negotiation as provided
in Section 12.2 shall be resolved in the following matter:

1. APPOINTMENT OF EXPERT. Within 10 Business Days after a party requests
pursuant to Section 12.2 that an expert be appointed to resolve a Technical
Dispute, the parties shall jointly appoint a mutually acceptable expert with
experience and expertise in the subject matter of the dispute. If the parties
are unable to so agree within such 10 Business Day period, or in the event of
disclosure of a conflict by an expert pursuant to paragraph 2 hereof which
results in the parties not confirming the appointment of such expert, then an
expert (willing to act in that capacity hereunder) shall be appointed by an
experienced arbitrator on the roster of the American Arbitration Association.

2. CONFLICTS OF INTEREST. Any person appointed as an expert shall not be
entitled to act and continue to act as such notwithstanding that at the time of
his appointment or at any time before he gives his determination, he has or may
have some interest or duty which conflicts or may conflict with his appointment
without the express written consent of the parties.

3. NOT ARBITRATOR. No expert shall be deemed to be an arbitrator and the
provisions of The American Arbitration Act or of any other applicable statute
(foreign or domestic) and the law relating to arbitration shall not apply to any
such expert or the expert's determination or the procedure by which the expert
reaches his determination to be made pursuant to this Schedule F.

4. PROCEDURE. Where an expert is appointed:

     (a)  Timing. The expert shall be so appointed on condition that (i) he
          promptly fixes a reasonable time and place for receiving
          representations, submissions or information from the parties and that
          he issues such authorizations to the parties and any relevant third
          party for the proper conduct of his determination and any hearing and
          (ii) he renders his decision (with full reasons) within 15 Business
          Days (or such other date as the parties and the expert may agree)
          after receipt of all information requested by him pursuant to
          paragraph 4(b) hereof.

     (b)  Disclosure of Evidence. The parties undertake one to the other to
          provide to any expert all such non-privileged evidence and information
          within their respective possession or control as the expert may
          reasonably consider necessary for determining the matter before him
          which they shall disclose promptly and in any event within five
          Business Days of a written request from the relevant expert to do so.

Oct. 25, 2002

<PAGE>

     (c)  Advisors. Each party may appoint such counsel, consultants and
          advisors as it feels appropriate to assist the expert in his
          determination and so as to present their respective cases so that at
          all times the parties shall co-operate and seek to narrow and limit
          the issues to be determined.

     (d)  Appointment of New Expert. If within the time specified in paragraph
          4(a) above the expert shall not have rendered a decision in accordance
          with his appointment, a new expert may (at the request of either
          party) be appointed and the appointment of the existing expert shall
          thereupon cease for the purposes of determining the matter at issue
          between the parties save that if the existing expert renders his
          decision with full reasons prior to the appointment of the new expert,
          then such a decision shall have effect and the proposed appointment of
          the new expert shall be withdrawn.

     (e)  Final and Binding. The determination of the expert shall, save in the
          event of fraud or manifest error, be final and binding upon the
          parties.

     (f)  Costs. Each party shall bear its own costs in connection with any
          matter referred to an expert hereunder and, in the absence of express
          provision in the Agreement to the contrary, the costs and expenses of
          the expert shall be shared equally by the parties.

For greater certainty, the parties agree that the release of the Products for
sale or distribution pursuant to the applicable marketing approval for such
Products shall not by itself indicate compliance by Patheon with its obligations
in respect of the Manufacturing Services and further that nothing in this
Agreement (including this Schedule F) shall remove or limit the authority of the
relevant qualified person (as specified by the Quality Agreement) to determine
whether the Products are suitable to be released for sale or distribution.

                                       -2-

<PAGE>

                                   SCHEDULE G

                                QUALITY AGREEMENT

                                QUALITY AGREEMENT

THIS AGREEMENT made as of the 7th day of April, 2005.

BETWEEN: CRITIAL THERAPEUTICS, INC.,

         a corporation existing under the laws of Delaware,

         (hereinafter referred to as the "CLIENT")

                                     - and -

         PATHEON PHARMACEUTICALS INC.,

         a corporation existing under the laws of Delaware,

         Specific sites covered by this Agreement:

         Cincinnati

         (hereinafter referred to as "PATHEON")

Oct. 25, 2002

<PAGE>

          WHEREAS pursuant to a manufacturing services agreement to be entered
into between Patheon and the Client (the "MSA"), Patheon will agree to provide
pharmaceutical manufacturing services in respect of certain Products (as
described in Schedule A hereto);

          AND WHEREAS pursuant to the MSA, the Client will be required to
provide certain information to Patheon in order for Patheon to provide the
Manufacturing Services (the "SPECIFICATIONS");

          AND WHEREAS pursuant to the MSA, Patheon will be required to operate
within the Specifications as provided;

          AND WHEREAS the parties desire to allocate the responsibility for
procedures and specifications impacting on the identity, strength, quality and
purity of the Products;

          NOW THEREFORE in consideration of the rights conferred and the
obligations assumed under the MSA and herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each
party), and intending to be legally bound the parties agree as follows:

<PAGE>

                                    ARTICLE 1

                                RESPONSIBILITIES

1.1 Subject to the terms and conditions hereinafter set out the parties agree
that Patheon shall be responsible for all the operations that are marked with
"X" in the column titled "Patheon" and that the client shall be responsible for
all the operations that are marked with "X" in the column titled "Client". If
marked with "(X)", cooperation is required from the designated party.

     (a)  General

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Provide Specifications                                       X

2.    Manufacturer and package Product in strict adherence to
      the Specifications

3.    Permit audits of all relevant premises, procedures and                X
      documentation by Client, and permit inspection by
      regulatory authorities.

4.    Not to subcontract any of the work to a third party                   X
      without prior consent. The parties agree that Patheon
      may subcontract laboratory testing to other Patheon
      facilities and to other third party laboratories.
      Patheon to qualify subcontractor's vendors.

5.    Provide copies of all information and correspondence                  X
      necessary to support the Annual Report when requested
      by Client.

6.    Notify and obtain approval from the Client prior to                   X
      implementation of any proposed changes to the process,
      materials, testing, equipment or premises that may
      affect the Product, such as Client approval not to be
      unreasonably withheld.
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
7.    Notify the Client within one Business Day of receipt of               X
      any Form 483's, warning letters or the like from
      applicable regulatory agencies relating to: (i) the
      Product; or (ii) if the supply of Products will be
      affected, the facilities used to product, test or
      package the Product. Reponses related to the Product
      shall be reviewed and approved by Client prior to
      submission to the applicable regulatory agency,
      provided that Patheon reserves the right to respond to
      such regulatory agencies without approval, if, in the
      reasonable opinion of Patheon's counsel, it is required
      to do so.

8.    Notify the Client within one Business Day of any                      X
      regulatory authority requests for Product samples,
      batch documentation, or other information related to
      the Product.

9.    Conduct operations in compliance with applicable                      X
      environmental, occupational health and safety laws and
      cGMP regulations.
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
10.   Investigate and resolve all medical and non-medical          X       (X)
      Product complaints.

11.   Investigate all manufacturing type product complaints.      (X)       X

12.   Initiate and control a Product recall.                       X       (X)

13.   Notify client within one business day upon receipt of                 X
      information meeting NDA Field Alert criteria.

14    Initiate NDA Field Alerts.                                   X       (X)

15.   Liaise with Regulatory Authorities for approval,             X
      maintenance and updating of marketing approval in a
      timely manner.
</TABLE>

     (b)  Validation and Process Testing Activities

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Establish applicable master validation plans and             X        X
      maintain a validation program for the Product.

2.    Qualify (IQ/OQ) facilities, utilities and process                     X
      equipment.

3.    Calibrate instrumentation and qualify computer systems                X
      used in the manufacture and testing of the Product.
</TABLE>

<PAGE>

<TABLE>
<S>   <C>                                                         <C>       <C>
4.    Prepare and approve all performance qualification and       (X)       X
      process validation protocols and reports, for
      manufacturing, packaging, and analytical testing
      operations.

5.    Review and approve master validation plan, performance       X        X
      qualification and process validation protocols for the
      Product.

6.    Maintain an appropriate cleaning and cleaning                         X
      validation program.

7     Provide toxicological information to be used in the          X
      development of a cleaning program.

8.    Validate analytical test methods for finished Product.       X        X
</TABLE>

     (c)  Raw Materials

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Provide the master formula.                                  X
</TABLE>

<PAGE>

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
2.    Provide approved supplier list. Client to audit and          X
      approve ACTIVE MATERIAL suppliers and ensure cGMP
      compliance. Client stipulated supplier shall be
      included on Client's approved supplier list (attached
      hereto as Schedule D).

3.    Provide approved supplier list. Client to audit and          X        X
      approve product specific EXCIPIENT SUPPLIERS and ensure
      cGMP compliance. Client stipulated supplier shall
      be included on Client's approved supplier list
      (attached hereto as Schedule D). Patheon to audit and
      approve excipient suppliers and ensure cGMP compliance
      where Patheon stipulates the supplier. Patheon
      stipulated suppliers shall be included on Patheon's
      approved supplier list (Schedule C).

4.    Provide Active Materials specifications.                     X

5.    Procure Active Materials (including Certificates of          X       (X)
      Analysis).

6.    Provide test methods for Active Materials (if                X
      non-Compendial).

7.    Validate non-Compendial testing methods for Active           X        X
      Materials.

8.    Analyze and release Active Materials (including              X        X
      documentation and Certificates of Analysis).

9.    Retain reference sample of Active Materials for one                   X
      year past the expiration date of the last batch of
      Product manufactured with that material in the
      Product or such longer period required by law.

10.   Procure excipients (including Certificates of                         X
      Analysis).

11.   Provide test methods and method validation for               X
      excipients (if non-Compendial).

12.   Analyze and release excipients (including documentation               X
      and Certificates of Analysis).
</TABLE>

<PAGE>

<TABLE>
<S>   <C>                                                       <C>      <C>
13.   Retain reference samples of excipients for one year                   X
      past the expiration date of the last batch manufactured
      with that material in the Product or such longer
      period as required by law.

14.   Provide to Client, at Client's request, by means of a                 X
      BSE/TSE certificate of compliance from the raw material
      vendor, confirmation of any bovine, caprine, or ovine
      derived raw materials purchased by Patheon for the
      manufacture of Product.

15.   Maintain records and evidence on the testing of raw                   X
      materials for five years after the materials were last
      used in the manufacture of the Product.
</TABLE>

<PAGE>

     (d)  Bulk Manufacture

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Create, control, issue and execute master batch record.               X

2.    Approve master batch record.                                 X        X

3.    Document, investigate and resolve deviations from           (X)       X
      approved manufacturing instructions or specifications.
      Report and obtain approval from Client QA regarding
      major deviations (incidents where there is a potential
      to affect Product quality).
</TABLE>

     (e)  Packaging

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Create, control, issue and execute master packaging                   X
      record.

2.    Approve master packaging record.                                      X

3.    Provide artwork and labeling test (blister, carton,          X       (X)
      leaflet, label etc.) specifications.

4.    Review and approve labeling proofs.                          X       (X)

5.    Provide specifications for packaging components.             X        X

6.    Qualify and approve packaging component suppliers.           X        X
      Client to audit product specific packaging component
      suppliers and ensure cGMP compliance where the Client
      stipulates the supplier unless the supplier is already
      in use by Patheon. Client stipulated supplier shall be
      included on its approved supplier list (attached hereto
      as Schedule D). Patheon to audit and approve packaging
      component suppliers and ensure cGMP compliance where
      Patheon stipulates the supplier. Patheon stipulated
      supplier shall be included on its approved supplier
      list (Schedule C).
</TABLE>

<PAGE>

<TABLE>
<S>   <C>                                                       <C>      <C>
7.    Provide test methods for packaging components. Where        (X)       X
      applicable, Patheon will provide such test methods and
      validation for packaging components purchased from
      suppliers on the Patheon approved supplier list only
      (Schedule C).

8.    Procure packaging components.                                         X

9.    Analyze and release packaging components.                             X

10.   Retain reference samples of finished Product for one                  X
      year past Product expiry or such longer period as
      required by law.

11.   Document, investigate and resolve any deviation from        (X)       X
      approved packaging instructions or specifications.
      Report and obtain approval from Client QA regarding
      major deviations.

12.   Maintain records and evidence on the testing of                       X
      packaging/labeling materials for five years after the
      materials were last used in the packaging/labelling of
      the Product.
</TABLE>

     (f)  Testing & Release of Finished Product

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>   <C>                                                       <C>      <C>
1.    Provide finished Product specifications.                     X

2.    Supply / develop analytical test methods for finished        X        X
      Product.

3.    Test finished Product.                                                X

4.    Maintain all master and executed batch records for a                  X
      minimum of one year past Product expiry date and supply
      all such records to the Client upon request.

5.    Maintain records and evidence on the testing of                       X
      finished product for one year after the expiration of
      the Product.

6.    Notify Client QA of confirmed Out-Of-Specification           X        X
      results ("OOS") within one Business Day; Patheon to
      generate deviation report and obtain approval from
      Client QA.
</TABLE>

<PAGE>

     (g)  Stability Testing

<TABLE>
<CAPTION>
                                                                CLIENT   PATHEON
                                                                ------   -------
<S>                                                             <C>      <C>
1.    Store stability samples.                                              X

2.    Develop and validate stability indicating assay.            (X)       X

3.    Provide stability testing protocol for finished              X        X
      Product.

4.    Perform stability testing.                                            X

5.    Notify the Client of any stability failure for Product                X
      supplied to the Client.
</TABLE>

                          ARTICLE 2

       COMPLIANCE BETWEEN PRODUCT REGISTRATION AND THE

                    MANUFACTURING PROCESS

2.1 Technical Changes

     (a)  All proposed process changes shall be communicated to the Client for
          initial review and approval, such Client approval not to be
          unreasonably withheld. The Client shall be responsible for determining
          whether or not to initiate registration variation procedures and for
          maintaining adequate control over the quality commitments of the
          marketing authorization made to the regulatory authorities by the
          Client for Products.

     (b)  Following validation of a process change, Patheon shall deliver a copy
          of the related validation report including data to the client and the
          associated stability data, if applicable, as it becomes available.

<PAGE>

2.2 Labelling / Packaging Material Changes.

          The client may initiate changes and shall review and approve any
Patheon-proposed changes to labelling or product contact packaging, including a
change in the supplier of any labelling or product contact packaging materials
before any such change may be implemented.

2.3 Other Changes

          Patheon will communicate any proposed changes in storage or shipping
to the Client for prior review and approval, such Client approval not to be
unreasonably withheld. Patheon will also inform the Client of any planned
changes in facilities or equipment that may impact Product(s).

2.4 Permits

          The client shall be solely responsible for obtaining or maintaining,
on a timely basis, any permits or other regulatory approvals in respect of the
Products or the Specifications, including, without limitation, all marketing and
post-marketing approvals.

                                    ARTICLE 3

                                  BATCH RELEASE

3.1 Batch review and release to Client shall be the responsibility of Patheon
who shall act in accordance with Patheon's standard operating procedures.

3.2 For each batch released by Patheon for shipment to the Client, Patheon shall
deliver to the Client a certificate of analysis/certificate of compliance, which
shall include a statement that the batch has

<PAGE>

been manufactured in accordance with cGMPs and the Specifications. The Client
shall have sole responsibility for release of the Product to the market.

3.3 Patheon shall notify the Client in the event of (i) any major deviation
during manufacture which affects the quality or efficacy of the Product or (ii)
a confirmed OOS result.

                                    ARTICLE 4

                               BATCH DOCUMENTATION

4.1 Originals of all batch documentation and associated retain samples will be
retained by Patheon for a period of one year past the expiry date of the Product
at which time the Client will be contacted concerning the future storage or
destruction of the documentation. Client to have option of taking ownership of
completed batch records, copies of analytical data, and product retains at the
end of the storage period.

4.2 At the request of the Client, Patheon agrees to provide a copy of any of the
executed batch documents relating to Products to the Client by facsimile or
courier within two Business Days.

                                    ARTICLE 5

                                    STABILITY

5.1 Patheon shall perform such stability testing as described in a stability
protocol agreed to by both Patheon and the Client.

<PAGE>

5.2 If a confirmed result indicates that a Product has failed to remain within
stability specifications, Patheon will notify the client within one Business
Day.

5.3 Stability data will be provided by Patheon to the Client on an ongoing basis
as agreed to by both parties.

5.4 In the event that the MSA is terminated, Patheon will continue to provide
the Client with stability data supporting the acceptability of the Product until
all such Product distributed by the Client has reached the end of its
shelf-life.

                                    ARTICLE 6

                                   VALIDATION

6.1 Client must ensure that their analytical methods and manufacturing
procedures (including packaging procedures) are validated.

6.2 If such methods and procedures are not validated by the Client, then Patheon
may assist in validation development with the costs being borne by the Client.

                                    ARTICLE 7

                                     GENERAL

7.1 Any communications with respect to the subject matter of this Agreement
shall be directed, in the first instance, to the person(s) identified in
Schedule B hereto.

<PAGE>

7.2 Capitalized terms not otherwise defined herein shall have the meaning
specified in the MSA.

<PAGE>

7.3 To the extent of any inconsistency between the terms of this Quality
Agreement and the terms of the MSA the terms of the MSA shall govern.

CRITICAL THERAPEUTICS, INC.,            PATHEON PHARMACEUTICALS INC.,

Name: /s/ Melody Hebert                 Name: /s/ Jack Domet
      -------------------------------         ----------------------------------

Signature: /s/ Melody Hebert            Signature: /s/ Jack Domet
           --------------------------              -----------------------------

Date: 6 April 2005                      Date: 4/7/05

<PAGE>

                                   SCHEDULE A

                                   PRODUCT(S)

<TABLE>
<CAPTION>
         PRODUCT(S)           GALENIC FORM   DOSAGE (STRENGTH)
         ----------           ------------   -----------------
<S>                           <C>            <C>
Zyflo IR Tablets (Zileuton)     Zileuton           600 mg
</TABLE>

<PAGE>

                                   SCHEDULE B

                                QUALITY CONTACTS

Critical Therapeutics, Inc.:            Patheon Pharmaceuticals Inc.:

Attention: Carole Varanelli             Attention: David Leuck

Phone: 781-402-5763                     Phone: 513-948-6358

Fax No.: 781-402-5728                   Fax No.: 513-948-7393

Alternate: Mel Hebert                   Alternate: Chuck Venable

Phone: 781-402-6201                     Phone: 513-948-7783

Fax No. 781-402-5728                    Fax No. 513-948-7854

<PAGE>

                                   SCHEDULE C

                         PATHEON APPROVED SUPPLIER LIST

<TABLE>
<S>                          <C>
Sodium Starch Glycolate      [**]

Starch Pregelantized         [**]

Hydroxpropylcellulose        [**]

Microcrystalline Cellulose   [**]

Crospovidone                 [**]

Talc                         [**]

Magnesium Stearate           [**]

Propylene Glycol             [**]

Titanium Dioxide             [**]

Bottles                      [**]

Caps                         [**]

Desiccant                    [**]
</TABLE>

<PAGE>

                                   SCHEDULE D

                          CLIENT APPROVED SUPPLIER LIST

<TABLE>
<S>            <C>
Zileuton       Rhodia

Hypromellose   [**]
</TABLE>

<PAGE>

                                   SCHEDULE H

                   QUARTERLY ACTIVE MATERIAL INVENTORY REPORT

TO:     Critical Therapeutics, INC.

FROM:   PATHEON INC.

RE:     Active Material quarterly inventory report pursuant to Section 2.3(a) of
        the Manufacturing Services Agreement dated - (the "Agreement")

<TABLE>
<S>                                              <C>
Reporting quarter:                                _______________________

Active Material on hand at beginning of quarter:  _______________________ kg (A)

Active Material on hand at end of quarter:        _______________________ kg (B)

Quantity Received during quarter:                 _______________________ kg (C)

Quantity Dispensed(1) during quarter:             _______________________ kg
(A + C - B)

Quantity Converted during quarter:                _______________________ kg
(total Active Material in Products produced)

Credit Received(2) during quarter:               $_______________________
</TABLE>

Capitalized terms used in this report have the meanings given to such terms in
the Agreement.

DATE:
      -------------------------------

----------
(1)  Excludes any Active Materials received or consumed in connection with
     technical transfer activities or development activities, including, without
     limitation, any regulatory, stability, validation or test batches
     manufactured during the month.

(2)  Amounts paid by Patheon during the month for Active Materials in respect of
     Product deficiencies in accordance with Section 6.1 and Product Recalls in
     accordance with Section 6.2 of the Agreement. [NOTE TO DRAFT: CONSIDER
     FOOTNOTE IN RESPECT OF SECTION 5.5(C)]

<PAGE>

PATHEON INC.

Per:
     --------------------------------
Name:
      -------------------------------
Title:
       ------------------------------

<PAGE>

                                                                        05/06/02

                                   SCHEDULE I

          REPORT OF ANNUAL ACTIVE MATERIAL INVENTORY RECONCILIATION AND
                       CALCULATION OF ACTUAL ANNUAL YIELD.

TO:     Critical Therapeutics, INC.

FROM:   PATHEON INC.

RE:     Active Material annual inventory reconciliation report and calculation
        of Actual Annual Yield pursuant to Section 2.3(a) of the Manufacturing
        Services Agreement dated o (the "Agreement")

<TABLE>
<S>                                              <C>
Reporting Year ending:                            _______________________

Active Material on hand at beginning of Year:     _______________________ kg (A)

Active Material on hand at end of Year:           _______________________ kg (B)

Quantity Received during Year:                    _______________________ kg (C)

Quantity Dispensed(3) during Year:                _______________________ kg (D)
(A + C - B)

Quantity Converted during Year:                   _______________________ kg (E)
(total Active Material in Products produced)

Credit Received(4) during Year:                  $_______________________    (F)

Active Material Cost:                            $_______________________/kg (G)

Target Yield:                                     _______________________%   (H)

Actual Annual Yield:                              _______________________%   (I)
((E/D) * 100)

Shortfall:                                       $_______________________    (J)
(((H - 3 - I)/100) * G * D)                       (if a negative number,
                                                       insert zero)
</TABLE>

Reimbursement calculation:

----------
(3)  Excludes any Active Materials received or consumed in connection with
     technical transfer activities or development activities, including, without
     limitation, any regulatory, stability, validation or test batches
     manufactured during the Year.

(4)  Amounts paid by Patheon during the Year for Active Material in respect of
     Product deficiencies in accordance with Section 6.1 and Recalls in
     accordance with Section 6.2 of the Agreement.

<PAGE>

<TABLE>
<CAPTION>
                                               reimbursement   reimbursement
test(s)                                          to Client      to Patheon
-------                                        -------------   -------------
<S>                                            <C>             <C>
J = zero                                       Nil             $F
J not equal to zero, and J = F                 Nil             nil
J not equal to zero, and J is greater than F   $(J - F)        nil
J not equal to zero, and F is greater than J   Nil             $(F - J)
</TABLE>

Based on the foregoing reimbursement calculation _________________ will
reimburse _________________ the amount of $_________________.

Capitalized terms used in this report have the meanings given to such terms in
the Agreement.

DATE:
      -------------------------------

PATHEON INC.

Per:
     --------------------------------
Name:
      -------------------------------
TITLE:
       ------------------------------

                                       25

<PAGE>

                                   SCHEDULE J

                            CONFIDENTIALITY AGREEMENT

                            CONFIDENTIALITY AGREEMENT

EFFECTIVE DATE: MAY 20, 2004

PARTIES:

<TABLE>
<S>                                <C>                            <C>
PATHEON INC.                       PATHEON PHARMACEUTICALS INC.   CRITICAL THERAPEUTICS, INC.
7070 Mississauga Road, Suite 350   2110 East Galbraith Road       60 Westview Street
Mississauga, ON L5N 7J8            Cincinnati, OH 45215           Lexington, MA  02421
</TABLE>

This Confidentiality Agreement (the "AGREEMENT") is entered into as of the
Effective Date by and between the parties identified above. As used herein, the
party disclosing information shall be referred to as the "DISCLOSING PARTY" and
the party or parties receiving such information shall be referred to as the
"RECIPIENT".

As a condition of the Disclosing Party furnishing any Information (defined
below) to the Recipient, the parties agree as follows:

1. INFORMATION. "INFORMATION" is any information disclosed by the Disclosing
Party to the Recipient (whether disclosed in oral, written, electronic or visual
form) that is non-public, confidential or proprietary including, without
limitation, information relating to the Disclosing Party's intellectual
property, its customers, finance, marketing, products research, data, know-how
and processes. Information shall be marked or clearly identified as such prior
to or at the time of disclosure. All analyses, compilations, studies, reports or
other documents prepared by any party's directors, officers, employees,
advisers, agents, consultants or representatives (collectively,
"REPRESENTATIVES") containing such Information and all price quotations,
manufacturing or professional services proposals and other information relating
to Patheon's manufacturing capabilities and operations shall be deemed to be
Information.

2. USE OF INFORMATION. The Recipient shall use the Information solely for the
purpose of investigating and implementing a potential business relationship
between the parties (the "PURPOSE"). The Recipient shall keep the Information
strictly confidential and shall not disclose the Information in any manner
whatsoever, in whole or in part, other than to those of its Representatives who
(i) have a need to know such Information for the Purpose and (ii) have entered
into a confidentiality agreement with the Recipient that is reasonably
calculated to protect the confidential or proprietary nature of the Information
and prohibit its disclosure. Recipient shall protect the Information by using
all reasonable precautions to prevent the unauthorized disclosure of the
Information, which precautions shall in no event be less than the Recipient's
treatment of its own confidential or proprietary information of a similar
nature.

3. EXCLUSIONS. The obligations of confidentiality set forth in Section 2 shall
not apply to Information to the extent that such Information:

     (a)  is or becomes publicly known through no fault of the Recipient or its
          Representatives;

     (b)  is in the Recipient's possession at the time of disclosure by the
          Disclosing Party other than as a result of the Recipient's breach of
          any legal obligation;

     (c)  is or becomes known to the Recipient through disclosure by sources,
          other than the Disclosing Party, having the legal right to disclose
          such Information;

     (d)  is independently developed by or for the Recipient without use of or
          reference to the Disclosing Party's Information as evident by
          Recipient's written records;

     (e)  is expressly authorized for release by the written authorization of
          the Disclosing Party; or

     (f)  is required to be disclosed by law (or rules of any self-regulatory
          organization having the force of law) or by any regulatory or
          governmental authority, provided that the Recipient promptly notifies
          the Disclosing Party and makes reasonable efforts to maintain the
          confidentiality of the Information in any required disclosure.

Any combination of information which comprises part of the Information shall not
be deemed to be exempt from the obligations of confidentiality merely because
individual parts of that information were publicly known, in the Recipient's
possession, or received by the Recipient, unless the combination itself was
publicly known, in the Recipient's possession, or received by the Recipient.

4. MARKING. The Disclosing Party agrees to use reasonable efforts to summarize
in writing the content of any oral disclosure or other non-tangible disclosure
of Information within 30 days of the disclosure, but

                                       26

<PAGE>

failure to provide such summary shall not affect the nature of the Information
disclosed if such Information was identified as confidential or proprietary when
disclosed orally or in any other non-tangible form.

5. RETURN OF INFORMATION. Upon the request of the Disclosing Party, the
Recipient shall promptly return to the Disclosing Party or, if the Disclosing
Party directs in writing, destroy all Information disclosed in or reduced to
tangible form including any copies thereof and shall destroy any summaries,
compilations, analyses or other notes derived from the Information except for
one copy which shall be maintained by the Recipient only if it is necessary to
maintain a copy for any legal or regulatory requirement.

6. REMEDIES. The parties acknowledge that monetary damages would not be
sufficient to remedy a breach by either party of this Agreement and agree that
each party shall be entitled to seek injunctive relief to prevent breaches of
this Agreement and to specifically enforce the provisions hereof in addition to
any other remedies available at law or in equity.

7. NO WARRANTY. All Information is provided "as is" and without any
representation or warranty, whether express or implied, as to its accuracy or
completeness.

8. RIGHTS. Neither party acquires any intellectual property rights, including
patents, designs, trade-marks, copyright or trade secrets under this Agreement,
except the limited right to use the Information to carry out the Purpose.

9. TERMINATION. This Agreement shall terminate on the earlier of (i) five years
after the Effective Date, or (ii) the written agreement of the parties.
Notwithstanding the earlier termination of this Agreement, the obligations of
confidentiality set forth herein shall continue for five years from the date of
disclosure of Information hereunder.

10. DATA TRANSFER. Unless otherwise agreed in writing, any personally
identifiable information provided by one party to the other hereunder may only
be used for conducting the business transaction(s) that is the subject of this
Agreement. Neither party consents to the other party's use of any personally
identifiable information provided by the Disclosing Party or its Representatives
for any direct marketing, nor to the transfer of such information to any third
party.

11. GENERAL.

(a)  This Agreement constitutes the full understanding between the parties with
     respect to the subject matter hereof and supersedes all prior agreements
     and understandings, whether written or oral, relating thereto.

(b)  No amendment or waiver of any provision of this Agreement shall be binding
     unless given in writing by the party to be bound thereby.

(c)  No failure or delay by either party in exercising any right hereunder shall
     operate as a waiver thereof.

(d)  This Agreement shall be binding on, and shall enure to the benefit of the
     parties and their respective successors.

(e)  This Agreement shall be governed by the laws of the State of Deleware.

(f)  This Agreement is not assignable by the parties. Any purported assignment
     of this Agreement shall be void.

(g)  Should any provision of this Agreement be found invalid or unenforceable by
     law, it shall cease to operate and be considered severed from this
     Agreement. All remaining provisions shall continue to be valid and binding
     on the parties.

(h)  This Agreement may be executed in separate counterparts, and by facsimile,
     each of which when so executed and delivered shall be an original and all
     such counterparts shall together constitute one and the same instrument.

                                       27

<PAGE>

                                                                        05/06/02

PATHEON INC.                            CRITICAL THERAPEUTICS, INC.

By: /s/ Riccardo Trecroce               By: /s/ T. Phillips
    ---------------------------------       ------------------------------------
Name: Riccardo Trecroce                 Name: T. Phillips
Title: General Counsel &                Title: COO
       Senior Vice President            Date: June 9, 2004
       Corporate Administration
Date: June 2, 2004

PATHEON PHARMACEUTICALS INC.

By: /s/ Riccardo Trecroce
    ---------------------------------
Name: Riccardo Trecroce
Title: Secretary
Date: June 2, 2004<PAGE>

                                                                    EXHIBIT 10.4

                  SUMMARY DESCRIPTION OF DIRECTOR COMPENSATION

Each member of the Board of Directors (the "Board") of Critical Therapeutics,
Inc. (the "Corporation") who is not an employee of the Corporation (a
"Non-Employee Director") will receive the following fees:

      -     $3,000 for each meeting of the Board, up to a maximum of five in any
            calendar year, that the Non-Employee Director attends in person;

      -     $1,500 for each meeting of any committee of the Board on which the
            director serves that the Non-Employee Director attends in person;
            and

      -     $1,000 for each meeting of the Board or any committee of the Board
            on which the director serves that the Non-Employee Director attends
            by teleconference.

The chair of the Audit Committee of the Board will receive an annual fee of
$2,500, the chair of the Compensation Committee of the Board will receive an
annual fee of $1,500 and the chair of our Nomination and Corporate Governance
Committee will receive an annual fee of $1,500. The Lead Independent Director
will receive an annual fee of $5,000. All fees for committee chairs and the Lead
Independent Director shall be paid at the beginning of each calendar year
(payments for partial years shall be made on a pro rata basis). All fees for
Board and committee meetings and teleconferences shall be paid shall be on a
quarterly basis retrospectively.

Each Non-Employee Director will also receive a nonstatutory option under the
Corporation's 2004 Stock Incentive Plan, as amended, or other stock incentive
plan approved by the Board and stockholders of the Corporation, to purchase up
to 25,000 shares of the Corporation's common stock ("Common Stock") upon his or
her initial election to the Board and an option to purchase up to 15,000 shares
of Common Stock at the first annual meeting following the completion of one
year's membership on the Board and at each year's annual meeting after which he
or she continues to serve as a director.

The per share exercise price of each Non-Employee Director option shall equal
the closing price of the Common Stock on the NASDAQ National Market (or on the
principal market on which the Common Stock is traded if other than the NASDAQ
National Market), on the date of grant (or if no such price is reported on such
date, such price as reported on the nearest preceding date). Such options shall
have a ten-year term. The shares subject to these options become exercisable in
36 equal monthly installments beginning one month from the date of grant. The
shares subject to these options shall be subject to appropriate adjustment for
stock splits, combinations, recapitalizations, and other similar events
affecting the Common Stock.

The Corporation shall reimburse each Non-Employee Director for reasonable travel
and other expenses incurred in connection with attending meetings of the Board
and its committees.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]